0001493152-23-039557.txt : 20231106 0001493152-23-039557.hdr.sgml : 20231106 20231106165534 ACCESSION NUMBER: 0001493152-23-039557 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20231031 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ITEM INFORMATION: Unregistered Sales of Equity Securities ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231106 DATE AS OF CHANGE: 20231106 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOTRICITY INC. CENTRAL INDEX KEY: 0001630113 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 472548273 STATE OF INCORPORATION: NV FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40761 FILM NUMBER: 231380588 BUSINESS ADDRESS: STREET 1: 203 REDWOOD PARKWAY STREET 2: SUITE 600 CITY: REDWOOD CITY STATE: CA ZIP: 94065 BUSINESS PHONE: (650) 832-1626 MAIL ADDRESS: STREET 1: 203 REDWOOD PARKWAY STREET 2: SUITE 600 CITY: REDWOOD CITY STATE: CA ZIP: 94065 FORMER COMPANY: FORMER CONFORMED NAME: METASOLUTIONS, INC. DATE OF NAME CHANGE: 20150107 8-K 1 form8-k.htm
false 0001630113 0001630113 2023-10-31 2023-10-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): October 31, 2023

 

BIOTRICITY INC.

(Exact name of registrant as specified in its charter)

 

Nevada   001-40761   30-0983531

(State or Other Jurisdiction of

Incorporation or Organization)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

203 Redwood Shores Parkway, Suite 600

Redwood City, California 94065

(Address of Principal Executive Offices)

 

(650) 832-1626

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Class   Trading Symbol (s)   Name of each exchange on which registered
Common Stock, Par Value $0.001   BTCY   Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 1.01. Entry into a Material Definitive Agreement.

 

Subscription Agreement

 

On October 31, 2023, Biotricity Inc. (the “Company”) entered into a subscription agreement (the “Agreement”) pursuant to which the Company issued an unsecured convertible preferred note (the “Note”) in the principal amount of $1,000,000 to an investor (“Investor”). The Note bears interest at a rate of 12% per annum, paid in cash monthly. The Note matures on the earlier of 18 months or there is more than one closing pursuant to the subscription agreement by the Company, the 18 month anniversary of the last closing date of the offering (the “Maturity Date”)

 

The Note and accrued interest may be prepaid by the Company in whole or in part in cash or through a conversion by the Investor at a price that is equal to a 15% discount to the 10-day VWAP. The Investor may at its option, convert all of the outstanding balance and accrued interest on the Note, at any time subsequent to a Qualified Financing consumed through earlier of the Early Payout Date  or the Maturity Date, as such terms as defined in the Note, at a conversion price equal to a 20% discount to the lesser of (i) the actual price per securities issued in the Qualified Financing or (ii) if there is no Qualified Financing as of the Maturity Date, by mutual consent and election of the Company and the Investor, at a 15% discount to the average VWAP for ten (10) consecutive trading days immediately prior to the Maturity Date .

 

The Note includes standard Events of Default, including, but not limited to: (i) failure to issue and deliver shares upon conversion, (ii) default in the payment of principal or interest, when same is due, (iii) the entry of a decree or order adjudging the Company as bankrupt or insolvent; or approving as properly filed a petition seeking reorganization, arrangement, adjustment or composition of or in respect of the Company, or appointing a receiver, liquidator, assignee, trustee or sequestrator (or other similar official) of the Company or of any substantial part of its property, or ordering the winding-up or liquidation of its affairs, and the continuance of any such decree or order unstayed and in effect for a period of 60 days; or (iv) institution by the Company of proceedings to be adjudicated as bankrupt or insolvent, or the consent by it to the institution of bankruptcy or insolvency proceedings against it, or the filing by it of a petition or answer or consent seeking reorganization or relief under the Federal Bankruptcy Code or any other applicable federal or state law.

 

The Note was issued and sold in reliance on exemption from registration afforded by Section 4(a)(2) of the Securities Act of 1933, as amended.

 

The foregoing description is qualified in its entirety by reference to the full text of the Note and the Agreement, copies of each of which are filed as Exhibit 4.1 and Exhibit 10.1 hereto, and each of which is incorporated herein by reference.

 

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

 

The information under Item 1.01 is incorporated by reference into this Item 2.03.

 

Item 3.02 Unregistered Sales of Equity Securities.

 

The information under Item 1.01 is incorporated by reference into this Item 3.02.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit Number   Description
4.1   Form of Promissory Note
10.1   Form of Subscription Agreement
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Date: November 6, 2023

 

  BIOTRICITY INC.
     
  By: /s/ Waqaas Al-Siddiq
    Waqaas Al-Siddiq
    Chief Executive Officer

 

 

EX-4.1 2 ex4-1.htm

 

Exhibit 4.1

 

fTHIS NOTE HAS NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, OR UNDER THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION, AND MAY NOT BE SOLD, ASSIGNED, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF EXCEPT IN COMPLIANCE WITH, OR PURSUANT TO AN EXEMPTION FROM, THE REQUIREMENTS OF SUCH ACT OR SUCH LAWS.

 

 

 

BIOTRICITY INC.

 

CONVERTIBLE PREFERRED NOTE

 

 

Principal Amount: US$[1,000,000] Issue Date: October 31, 2023

 

BIOTRICITY INC., a Nevada corporation (the “Company”), for value received, hereby promises to pay to [ ] (the “Subscriber(s)”) or his permitted assigns or successors (the “Holder(s)”), the principal amount of [One Million Dollars] (US$[1,000,000]) (the “Principal Amount”), without demand, on the Maturity Date (as hereinafter defined), together with any accrued and unpaid interest due thereon. This Note shall bear interest at a fixed rate of 12% per annum, paid in cash monthly. Except as set forth in Section 3.1, payment of all principal due shall be in such coin or currency of the United States of America as shall be legal tender for the payment of public and private debts at the time of payment.

 

This Note is a convertible preferred note referred to in that certain Subscription Agreement dated as of the date hereof (the “Subscription Agreement”), or series of like subscription agreements, among the Company and the Subscriber(s), pursuant to which the Company is seeking to raise an aggregate of up to $1,000,000 (the “Offering”).

 

ARTICLE 1

 

DEFINITIONS

 

SECTION 1.1. Definitions. The terms defined in this Article whenever used in this Note shall have the respective meanings hereinafter specified.

 

Applicable Laws” means any and all applicable foreign, federal, state and local statutes, laws, regulations, ordinances, policies, and rules or common law (whether now existing or hereafter enacted or promulgated), of any and all governmental authorities, agencies, departments, commissions, boards, courts, or instrumentalities of the United States, any state of the United States, any other nation, or any political subdivision of the United States, any state of the United States or any other nation, and all applicable judicial and administrative, regulatory or judicial decrees, judgments and orders, including common law rules and determinations.

 

1

 

 

Common Stock” means the common stock, par value $0.001 per share, of the Company.

 

Conversion Shares” means the New Round Stock issued or issuable to the Holder upon a Conversion Date pursuant to Article 3.

 

Conversion Date” shall have the meaning set forth in Section 3.1. “Event of Default” shall have the meaning set forth in Section 6.1.

 

Holder” or “Holders” means the person named above or any Person who shall thereafter become a recordholder of this Note in accordance with the terms hereof.

 

Issue Date” means the issue date stated above.

 

Maturity Date” shall mean the earlier of: (a) the eighteen (18) month anniversary of the date hereof or, if there be more than one closing pursuant to the Offering, the eighteen (18) month anniversary of the last closing date of the Offering.

 

New Round Stock” means, in the event of a Qualified Financing, the securities (or units of securities if more than one security are sold as a unit) issued by the Company in the Qualified Financing.

 

Note” means this Convertible Preferred Note, as amended, modified or restated.

 

Person” means an individual, corporation, partnership, limited liability company, association, trust, joint venture, unincorporated organization or any government, governmental department or agency or political subdivision thereof.

 

Qualified Financing” means the next equity or debt round of financing of the Company in whatever form or type, that raises in excess of $15,000,000 gross proceeds.

 

Securities Act” means the United States Securities Act of 1933, as amended. “Trading Day” means a day on which the principal Trading Market is open for trading.

 

Trading Market” means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE MKT, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York Stock Exchange (or any successors to any of the foregoing).

 

VWAP” means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if the Common Stock is not then listed or quoted for trading on a Trading Market and if prices for the Common Stock are then reported on the OTC Markets, Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (c) in all other cases, the fair market value of a share of Common Stock as determined by the Board of Directors of the Company in good faith.

 

2

 

 

ARTICLE 2

 

GENERAL PROVISIONS

 

SECTION 2.1. Loss, Theft. Destruction of Note. Upon receipt of evidence satisfactory to the Company of the loss, theft, destruction or mutilation of this Note and, in the case of any such loss, theft or destruction, upon receipt of indemnity or security reasonably satisfactory to the Company, or, in the case of any such mutilation, upon surrender and cancellation of this Note, the Company will make and deliver, in lieu of such lost, stolen, destroyed or mutilated Note, a new Note of like tenor and unpaid principal amount dated as of the date hereof. This Note shall be held and owned upon the express condition that the provisions of this Section 2.1 are exclusive with respect to the replacement of a mutilated, destroyed, lost or stolen Note and shall preclude any and all other rights and remedies notwithstanding any law or statute existing or hereafter enacted to the contrary with respect to the replacement of negotiable instruments or other securities without their surrender.

 

SECTION 2.2. Prepayment; Redemption. This Note may be prepaid by the Company in whole or in part, after providing fifteen (15) days written notice to the Holder, either in cash or by the mutually consented conversion of the Note and any accrued interest thereon at a 15% discount to the stock’s 10-day VWAP.

 

ARTICLE 3

 

CONVERSION OF NOTE

 

SECTION 3.1. Conversion.

 

(a) Optional Conversion Upon Qualified Financing or Maturity. At the option of the Holder at any time subsequent to the consummation of a Qualified Financing (the “Conversion Date”) through to the earlier of the Early Payout Date or the Maturity Date, all of the outstanding principal and accrued interest shall convert into New Round Stock based upon a conversion price equal to a 20% discount to the lesser of (i) the actual price per New Round Stock in the Qualified Financing or (ii) if there be no Qualified Financing as of the Maturity Date, by mutual consent and election of the Company and the Holder, at a 15% discount to the average VWAP for ten (10) consecutive Trading Days immediately prior to the Maturity Date.

 

(b) Upon and as of the Conversion Date, this Note will be cancelled on the books and records of the Company and shall represent the right to receive the Conversion Shares.

 

SECTION 3.2. Delivery of Securities Upon Conversion.

 

(a) As soon as is practicable after the Conversion Date, the Company shall deliver to the Holder (i) a certificate or certificates evidencing the Conversion Shares issuable to the Holder.

 

3

 

 

(b) The issuance of certificates for Conversion Shares upon conversion or maturity of this Note shall be made without charge to the Holder for any issuance tax in respect thereof or other cost incurred by the Company in connection with such conversion and the related issuance of securities. Upon conversion of this Note, the Company shall take all such actions as are necessary in order to ensure that the Conversion Shares so issued upon such conversion shall be validly issued, fully paid and nonassessable.

 

SECTION 3.3. Fractional Shares. No fractional shares or scrip representing fractional shares shall be issued upon conversion of this Note. If any conversion of this Note would create a fractional share or a right to acquire a fractional share, the Company shall round to the nearest whole number.

 

ARTICLE 4

 

STATUS; RESTRICTIONS ON TRANSFER

 

SECTION 4.1. Status of Note. This Note is a direct, general and unconditional obligation of the Company, and constitutes a valid and legally binding obligation of the Company, enforceable in accordance with its terms subject, as to enforcement, to bankruptcy, insolvency, reorganization and other similar laws of general applicability relating to or affecting creditors’ rights and to general principles of equity.

 

SECTION 4.2. Restrictions on Transferability. This Note and any Conversion Shares issued with respect to this Note, have not been registered under the Securities Act, or under any state securities or so-called “blue sky laws,” and may not be offered, sold, transferred, hypothecated or otherwise assigned except (a) pursuant to a registration statement with respect to such securities which is effective under the Act or (b) upon receipt from counsel satisfactory to the Company of an opinion, which opinion is satisfactory in form and substance to the Company, to the effect that such securities may be offered, sold, transferred, hypothecated or otherwise assigned (i) pursuant to an available exemption from registration under the Act and (ii) in accordance with all applicable state securities and so-called “blue sky laws.” The Holder agrees to be bound by such restrictions on transfer. The Holder further consents that the certificates representing the Conversion Shares that may be issued with respect to this Note may bear a restrictive legend to such effect.

 

ARTICLE 5

 

COVENANTS

 

In addition to the other covenants and agreements of the Company set forth in this Note, the Company covenants and agrees that so long as this Note shall be outstanding:

 

SECTION 5.1. Payment of Note. The Company will punctually, according to the terms hereof, (a) pay or cause to be paid all amounts due under this Note, (b) reasonably promptly issue the Conversion Shares upon the Conversion Date.

 

4

 

 

SECTION 5.2. Notice of Default. If any one or more events occur which constitute or which, with the giving of notice or the lapse of time or both, would constitute an Event of Default or if the Holder shall demand payment or take any other action permitted upon the occurrence of any such Event of Default, the Company will forthwith give notice to the Holder, specifying the nature and status of the Event of Default or other event or of such demand or action, as the case may be.

 

SECTION 5.3. Compliance with Laws and Filing Responsibilities. The Company will comply in all material respects with all Applicable Laws, except where the necessity of compliance therewith is contested in good faith by appropriate proceedings. The Company will be responsible for timely filing of all required documents including Form D, and blue sky filings, and will pay for all legal opinions of Company counsel associated with all future sales of the Investor appropriately relying on Rule 144 with respect to the securities sold.

 

SECTION 5.4. Use of Proceeds. The Company shall use the proceeds of this Note for general working capital.

 

ARTICLE 6

 

REMEDIES

 

SECTION 6.1. Events of Default. “Event of Default” wherever used herein means any one of the following events:

 

(a) The Company shall fail to issue and deliver the Conversion Shares in accordance with Article 3;

 

(b) Default in the due and punctual payment of the principal of, or any other amount owing in respect of (including Interest), this Note when and as the same shall become due and payable;

 

(c) Default in the performance or observance of any covenant or agreement of the Company in this Note (other than a covenant or agreement a default in the performance of which is specifically provided for elsewhere in this Section 6.1), and the continuance of such default for a period of ten (10) days after there has been given to the Company by the Holder a written notice specifying such default and requiring it to be remedied;

 

(d) The entry of a decree or order by a court having jurisdiction adjudging the Company as bankrupt or insolvent; or approving as properly filed a petition seeking reorganization, arrangement, adjustment or composition of or in respect of the Company under the Federal Bankruptcy Code or any other applicable federal or state law, or appointing a receiver, liquidator, assignee, trustee or sequestrator (or other similar official) of the Company or of any substantial part of its property, or ordering the winding-up or liquidation of its affairs, and the continuance of any such decree or order unstayed and in effect for a period of sixty (60) calendar days;

 

(e) The institution by the Company of proceedings to be adjudicated as bankrupt or insolvent, or the consent by it to the institution of bankruptcy or insolvency proceedings against it, or the filing by it of a petition or answer or consent seeking reorganization or relief under the Federal Bankruptcy Code or any other applicable federal or state law, or the consent by it to the filing of any such petition or to the appointment of a receiver, liquidator, assignee, trustee or sequestrator (or other similar official) of the Company or of any substantial part of its property, or the making by it of an assignment for the benefit of creditors;

 

5

 

 

(f) The Company seeks the appointment of a statutory manager or proposes in writing or makes a general assignment or an arrangement or composition with or for the benefit of its creditors or any group or class thereof or files a petition for suspension of payments or other relief of debtors or a moratorium or statutory management is agreed or declared in respect of or affecting all or any material part of the indebtedness of the Company; or

 

(g) It becomes unlawful for the Company to perform or comply with its obligations under this Note.

 

SECTION 6.2. Effects of Default. If an Event of Default occurs and is continuing, then and in every such case the Holder may declare this Note to be due and payable immediately, by a notice in writing to the Company, and upon any such declaration, the Company shall pay to the Holder the outstanding principal amount of this Note plus all accrued and unpaid interest through the date the Note is paid in full.

 

SECTION 6.3. Remedies Not Waived. No course of dealing between the Company and the Holder or any delay in exercising any rights hereunder shall operate as a waiver by the Holder. No failure or delay by the Holder in exercising any right, power or privilege under this Note shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power or privilege. The rights and remedies herein provided shall be cumulative and not exclusive of any rights or remedies provided by Applicable Law.

 

ARTICLE 7

 

MISCELLANEOUS

 

SECTION 7.1. Severability. If any provision of this Note shall be held to be invalid or unenforceable, in whole or in part, neither the validity nor the enforceability of the remainder hereof shall in any way be affected.

 

SECTION 7.2. Notice. Where this Note provides for notice of any event, such notice shall be given (unless otherwise herein expressly provided) in writing and either (i) delivered personally, (ii) sent by certified, registered or express mail, postage prepaid or (iii) sent by facsimile or other electronic transmission, and shall be deemed given when so delivered personally, sent by facsimile or other electronic transmission (confirmed in writing) or mailed. Notices shall be addressed, if to Holder, to its address as provided in the Subscription Agreement or, if to the Company, to its principal office.

 

SECTION 7.3. Governing Law. This Note shall be governed by, and construed in accordance with, the laws of the State of New York (without giving effect to any conflicts or choice of law provisions that would cause the application of the domestic substantive laws of any other jurisdiction).

 

6

 

 

SECTION 7.4. Forum. The Holder and the Company hereby agree that any dispute which may arise out of or in connection with this Note shall be adjudicated before a court of competent jurisdiction in the State of New York and they hereby submit to the exclusive jurisdiction of the courts of the County and State of New York, as well as to the jurisdiction of all courts to which an appeal may be taken from such courts, with respect to any action or legal proceeding commenced by either of them and hereby irrevocably waive any objection they now or hereafter may have respecting the venue of any such action or proceeding brought in such a court or respecting the fact that such court is an inconvenient forum.

 

SECTION 7.5. Headings. The headings of the Articles and Sections of this Note are inserted for convenience only and do not constitute a part of this Note.

 

SECTION 7.6. Amendments. Any provision of this Note may be amended, modified or waived if and only if the Holder of this Note and the Company has consented in writing to such amendment, modification or waiver of any such provision of this Note.

 

SECTION 7.7. No Recourse Against Others. The obligations of the Company under this Note are solely obligations of the Company and no officer, employee or stockholder shall be liable for any failure by the Company to pay amounts on this Note when due or perform any other obligation.

 

SECTION 7.9. Assignment; Binding Effect. This Note may not be assigned by the Company without the prior written consent of the Holder. This Note shall be binding upon and inure to the benefit of both parties hereto and their respective permitted successors and assigns.

 

SECTION 8.0. Registration Rights. If this Note is converted, shares underlying the Note will be subject to “piggy-back” registration rights of the Qualified Financing.

 

IN WITNESS WHEREOF, the Company has caused this Note to be signed by its duly authorized officer on the date hereinabove written.

 

  BIOTRICITY INC.
     
  By: /s/ Waqaas Alsiddiq
  Name: Waqaas Alsiddiq
  Title: CEO

 

7

 

EX-10.1 3 ex10-1.htm

 

Exhibit 10.1

 

SUBSCRIPTION AGREEMENT

 

THIS SUBSCRIPTION AGREEMENT (this “Agreement”) is dated as of the date contained in the signature page hereto (the “Closing Date”), by and between BIOTRICITY INC., a Nevada corporation (the “Company”), and the subscriber identified on the signature page hereto (the “Subscriber”).

 

RECITALS

 

WHEREAS, the Company seeks to sell Convertible Preferred Notes in the form annexed hereto as Exhibit B (the “Note” and collectively referred to as the “Notes”), pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”) and Rule 506(b) of Regulation D (“Regulation D”) as promulgated under the Securities Act (the “Offering”); and

 

WHEREAS, the Subscriber wishes to purchase a Note with the principal amount as set forth on the Signature Page to this Agreement;

 

NOW, THEREFORE, in consideration of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company and the Subscriber hereby agree as follows:

 

ARTICLE I

PURCHASE OF CONVERTIBLE PREFERRED NOTES

 

1.01 Subscription. The Subscriber hereby subscribes (the “Subscription”) to purchase a Note in the amount set forth on the signature page hereto (the “Subscription Amount”). This Subscription shall become effective when it has been duly executed by the Subscriber and this Agreement has been accepted and agreed to by the Company.

 

1.02 Payment For Subscription. The Subscriber agrees that the Subscription Amount to the Company for the amount of the Subscriber’s Subscription is to be made upon submission of this Agreement in the form included in these Subscription Documents (as hereinafter defined).

 

1.03 Terms and Conditions. The Company shall have the right to accept or reject the Subscription, in whole or in part, for any reason whatsoever, including, but not limited to, the belief of the Company that the Subscriber cannot bear the economic risk of an investment in the Company, is not capable of evaluating the merits and risks of an investment in the Company or is not an “Accredited Investor,” as such term is defined in Rule 501 of Regulation D promulgated under the Securities Act, or for no reason at all. A closing may occur once a Subscription is received by the Company and additional closings under the Offering may take place from time to time as subscriptions are received by the Company.

 

1.04 Conversion. At the option of the Holder at any time subsequent to the consummation of a Qualified Financing (the “Conversion Date”) through to the earlier of the Early Payout Date or the Maturity Date, all of the outstanding principal and accrued interest shall convert into New Round Stock based upon a conversion price equal to a 20% discount to the lesser of (i) the actual price per New Round Stock in the Qualified Financing or (ii) if there be no Qualified Financing as of the Maturity Date, by mutual consent and election of the Company and the Holder, at a 15% discount to the average VWAP for ten (10) consecutive Trading Days immediately prior to the Maturity Date.

 

1

 

 

ARTICLE II

REPRESENTATIONS AND WARRANTIES

 

2.01 Representations and Warranties by the Company. The Company represents and warrants to the Subscriber that:

 

(a) Authorization. The Company has all corporate right, power and authority to enter into this Agreement and to consummate the transactions contemplated hereby. All corporate action on the part of the Company, its directors and stockholders necessary for the: (i) authorization execution, delivery and performance of this Agreement by the Company; (ii) authorization, sale, issuance and delivery of the Notes contemplated hereby and the performance of the Company’s obligations hereunder; and (iii) authorization, issuance and delivery of the securities issuable upon conversion of the Notes, has been taken. The securities issuable upon conversion of the Notes will be validly issued, fully paid and nonassessable. The issuance and sale of the securities contemplated hereby will not give rise to any preemptive rights or rights of first refusal on behalf of any person which have not been waived in connection with this offering. The Company is not in default of any other obligations, including any promissory notes or debentures.

 

(b) Enforceability. Assuming this Agreement has been duly and validly authorized, executed and delivered by the parties hereto and thereto other than the Company, this Agreement as duly authorized, executed and delivered by the Company constitutes the legal, valid and binding obligations of the Company enforceable against the Company in accordance with its terms, except as such enforcement is limited by general equitable principles, or by bankruptcy, insolvency and other similar laws affecting the enforcement of creditors rights generally.

 

(c) No Violations. The execution, delivery and performance of this Agreement and the Note by the Company and the consummation by the Company of the transactions contemplated hereby and thereby (including, without limitation, the securities issuable upon the conversion of the Note) will not (i) result in a violation of the Articles of Incorporation of the Company or other organizational documents of the Company, (ii) conflict with, or constitute a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which the Company is a party, or (iii) result in a violation of any law, rule, regulation, order, judgment or decree applicable to the Company by which any property or asset of the Company is bound or affected.

 

(d) Litigation. The Company knows of no pending or threatened legal or governmental proceedings against the Company which could materially adversely affect the business, property, financial condition or operations of the Company or which materially and adversely questions the validity of this Agreement or any agreements related to the transactions contemplated hereby or the right of the Company to enter into any of such agreements, or to consummate the transactions contemplated hereby or thereby. The Company is not a party or subject to the provisions of any order, writ, injunction, judgment or decree of any court or government agency or instrumentality which could materially adversely affect the business, property, financial condition or operations of the Company. There is no material action, suit, proceeding or investigation by the Company currently pending in any court or before any arbitrator or that the Company intends to initiate.

 

(e) Intellectual Property. The Company owns or possesses sufficient legal rights to all patents, trademarks, service marks, trade names, copyrights, trade secrets, licenses, information and other proprietary rights and processes necessary for its business as now conducted without any known infringement of the rights of others. The Company has not received any written communications alleging that the Company has violated or, by conducting its business as presently proposed to be conducted, would violate any of the patents, trademarks, service marks, trade names, copyrights or trade secrets or other proprietary rights of any other person or entity.

 

2

 

 

(f) Title to Assets. The Company has good and marketable title to its properties and assets, and good title to its leasehold estates, in each case subject to no mortgage, pledge, lien, lease, encumbrance or charge, other than (a) those resulting from taxes which have not yet become delinquent; (b) liens and encumbrances which do not materially detract from the value of the property subject thereto or materially impair the operations of the Company; and (c) those that have otherwise arisen in the ordinary course of business. The Company is in compliance with all material terms of each lease to which it is a party or is otherwise bound.

 

(g) Investment Company. The Company is not an “investment company” within the meaning of such term under the Investment Company Act of 1940, as amended, and the rules and regulations of the Securities and Exchange Commission thereunder.

 

(h) No Solicitation. Neither the Company nor any person participating on the Company’s behalf in the transactions contemplated hereby has conducted any “general solicitation,” as such term is defined in Regulation D promulgated under the Securities Act, with respect to any of the Notes being offered hereby.

 

(i) Blue Sky. The Company agrees to file a Form D with respect to the sale of the Notes under Regulation D of the rules and regulations promulgated under the Securities Act. The Company shall, on or before the Closing Date, take such action as the Company shall reasonably determine is necessary to qualify the Notes for sale to the Subscriber pursuant to this Agreement under applicable securities or “blue sky” laws of the states of the United States (or to obtain an exemption from such qualification).

 

(j) The execution, delivery and performance of this Agreement by the Company will not (i) violate any law, treaty, rule or regulation applicable to or binding upon the Company or any of its properties or assets, or (ii) result in a breach of any contractual obligation to which the Company is a party or by which it or any of its properties or assets is bound that would reasonably be expected to have a material adverse effect on the ability of the Company to perform its obligations under this Agreement.

 

(k) There is no civil, criminal or administrative action, suit, demand, claim, hearing, notice of violation or investigation, proceeding or demand letter pending, or to the knowledge of the Company threatened, against the Company, which if adversely determined would reasonably be expected to have a material adverse effect on the ability of the Company to perform its obligations hereunder. There is no civil, criminal or administrative action, suit, demand, claim, hearing, notice of violation or investigation, proceeding or demand letter pending, or to the knowledge of the Company threatened, against or affecting the Company or any of its subsidiaries that, if adversely determined, would reasonably be expected to have a material adverse effect on the Company and its subsidiaries (taken as a whole). There are no outstanding orders, writs, judgments, decrees, injunctions or settlements that would reasonably be expected to have a material adverse effect on the Company and its subsidiaries (taken as a whole).

 

2.02 Survival of Representations and Warranties. The representations and warranties of the Company shall survive the closing and shall be fully enforceable at law or in equity against the Company and the Company’s successors and assigns.

 

2.03 Disclaimer. It is specifically understood and agreed by the Subscriber that the Company has not made, nor by this Agreement shall be construed to make, directly or indirectly, explicitly or by implication, any representation, warranty, projection, assumption, promise, covenant, opinion, recommendation or other statement of any kind or nature with respect to the anticipated profits or losses of the Company, except as otherwise provided with this Agreement.

 

3

 

 

2.04 Representations and Warranties by the Subscriber. The Subscriber represents and warrants to the Company that:

 

(a) The Subscriber is acquiring the Notes for the Subscriber’s own account, as principal, for investment purposes only and not with any intention to resell, distributes or otherwise dispose of the Notes, as the case may be, in whole or in part.

 

(b) The Subscriber has had an unrestricted opportunity to: (i) obtain information concerning the Offering, including the Notes, the Company and its proposed and existing business and assets; and (ii) ask questions of, and receive answers from the Company concerning the terms and conditions of the Offering and to obtain such additional information as may have been necessary to verify the accuracy of the information contained in the this Agreement or otherwise provided.

 

(c) The Subscriber is an Accredited Investor, within the meaning of Securities and Exchange Commission (“SEC”) Rule 501 of Regulation D, and has such knowledge and experience in financial and business matters that he is capable of evaluating the merits and risks of investing in the Company, and all information that the Subscriber has provided concerning the Subscriber, the Subscriber’s financial position and knowledge of financial and business matters is true, correct and complete. The Subscriber acknowledges and understands that the Company will rely on the information provided by the Subscriber in this Agreement and in the Subscriber Questionnaire annexed hereto as Exhibit A for purposes of complying with Federal and applicable state securities laws.

 

(d) Except as otherwise disclosed in writing by the Subscriber to the Company, the Subscriber has not dealt with a broker in connection with the purchase of the Notes and agrees to indemnify and hold the Company and its officers and directors harmless from any claims for brokerage or fees in connection with the transactions contemplated herein.

 

(e) The Subscriber is not relying on the Company or any of its management, officers or employees with respect to any legal, investment or tax considerations involved in the purchase, ownership and disposition of Notes. The Subscriber has relied solely on the advice of, or has consulted with, in regard to the legal, investment and tax considerations involved in the purchase, ownership and disposition of Notes, the Subscriber’s own legal counsel, business and/or investment adviser, accountant and tax adviser.

 

(f) The Subscriber understands that the Notes, or the securities into which either of them may convert or be exercised for, cannot be sold, assigned, transferred, exchanged, hypothecated or pledged, or otherwise disposed of or encumbered except in accordance with the Securities Act or the 1934 Securities and Exchange Act, as amended (the “Exchange Act”), and that no market will exist for the resale of any such securities. In addition, the Subscriber understands that the Notes, or the securities into which they may convert, have not been registered under the Securities Act, or under any applicable state securities or blue sky laws or the laws of any other jurisdiction, and cannot be resold unless they are so registered or unless an exemption from registration is available. The Subscriber understands that there is no current plan to register the Notes, or the securities into which they may convert.

 

(g) The Subscriber is willing and able to bear the economic and other risks of an investment in the Company for an indefinite period of time. The Subscriber has read and understands the provisions of this Agreement.

 

4

 

 

(h) The Subscriber maintains the Subscriber’s domicile, and is not merely a transient or temporary resident, at the residence address shown on the signature page of this Agreement.

 

(i) The Subscriber understands that the Company has made available to the Subscriber and the Subscriber’s accountants, attorneys and other advisors full and complete information concerning the financial structure of the Company, and any and all data requested by the Subscriber as a basis for estimating the potential profits and losses of the Company and the Subscriber acknowledges that the Subscriber has either reviewed such information or has waived review of such information.

 

(j) The Subscriber is not participating in the Offering as a result of or subsequent to: (i) any advertisement, article, notice or other communication published in any newspaper, magazine or similar media or broadcast over television or radio; (ii) any seminar or meeting whose attendees have been invited by any general solicitation or general advertising; or (iii) any registration statement the Company may have filed with the Securities and Exchange Commission.

 

(k) If the Subscriber is an entity, the Subscriber is duly organized, validly existing and in good standing under the laws of its jurisdiction of incorporation or organization, as the case may be. The Subscriber has all requisite power and authority to own its properties, to carry on its business as presently conducted, to enter into and perform the Subscription and the agreements, documents and instruments executed, delivered and/or contemplated hereby (collectively, the “Subscription Documents”) to which it is a party and to carry out the transactions contemplated hereby and thereby. The Subscription Documents are valid and binding obligations of the Subscriber, enforceable against it in accordance with their terms, except as enforceability may be limited by applicable bankruptcy, insolvency, moratorium, reorganization or similar laws, from time to time in effect, which affect enforcement of creditors’ rights generally. If applicable, the execution, delivery and performance of the Subscription Documents to which it is a party have been duly authorized by all necessary action of the Subscriber. The execution, delivery and performance of the Subscription Documents and the performance of any transactions contemplated by the Subscription Documents will not (i) violate, conflict with or result in a default (whether after the giving of notice, lapse of time or both) under any contract or obligation to which the Subscriber is a party or by which it or its assets are bound, or any provision of its organizational documents (if an entity), or cause the creation of any lien or encumbrance upon any of the assets of the Subscriber; (ii) violate, conflict with or result in a default (whether after the giving of notice, lapse of time or both) under, any provision of any law, regulation or rule, or any order of, or any restriction imposed by any court or other governmental agency applicable to the Subscriber; (iii) require from the Subscriber any notice to, declaration or filing with, or consent or approval of any governmental authority or other third party other than pursuant to federal or state securities or blue sky laws; or (iv) accelerate any obligation under, or give rise to a right of termination of, any agreement, permit, license or authorization to which the Subscriber is a party or by which it is bound.

 

(l) The Subscriber acknowledges and agrees that the Company intends, in the future, to raise additional funds to expand its business which may include, without limitation, the need to: fund more rapid expansion; fund additional marketing expenditures; enhance its operating infrastructure; hire additional personnel; respond to competitive pressures; or acquire complementary businesses or necessary technologies.

 

(m) The Subscriber acknowledges and agrees that the Company will have broad discretion with respect to the use of the proceeds from this Offering, and investors will be relying on the judgment of management regarding the application of these proceeds.

 

(n) The Subscriber understands the various risks of an investment in the Company, and has carefully reviewed the various risk factors described in the Company’s various public filings, including but not limited to its 10Qs and 10Ks.

 

5

 

 

ARTICLE III

MISCELLANEOUS

 

3.01 Indemnification.

 

(a) The Subscriber will, severally and not jointly with any other Subscribers indemnify and hold harmless the Company and its officers, directors, members, shareholders, partners, representatives, employees and agents, successors and assigns against any losses, obligations, claims, damages, liabilities, contingencies, judgments, fines, penalties, charges, costs (including, without limitation, court costs, reasonable attorneys’ fees and costs of defense and investigation), amounts paid in settlement or expenses, joint or several, (collectively, “Company Claims”) reasonably incurred in investigating, preparing or defending any action, claim, suit, inquiry, proceeding, investigation or appeal taken from the foregoing by or before any court or governmental, administrative or other regulatory agency, body or the SEC, whether pending or threatened, whether or not an indemnified party is or may be a party thereto, to which any of them may become subject insofar as such Company Claims (or actions or proceedings, whether commenced or threatened, in respect thereof): (a) arise out of or are based upon any untrue statement or untrue statement of a material fact made by the Subscriber and contained in this Agreement or (b) arise out of or are based upon any breach by the Subscriber of any representation, warranty, or agreement made by the Subscriber contained herein. Provided, however, and notwithstanding anything to the contrary, in no event shall the liability of the Subscriber pursuant to this Section exceed the amount of the Note that the Subscriber purchases pursuant to this Agreement.

 

(b) The Company will indemnify and hold harmless each Subscriber and its officers, directors, members, shareholders, partners, representatives, employees and agents, successors and assigns, and each other person, if any, who controls such Subscriber within the meaning of the Securities Act against any losses, obligations, claims, damages, liabilities, contingencies, judgments, fines, penalties, charges, costs (including, without limitation, court costs, reasonable attorneys’ fees and costs of defense and investigation), amounts paid in settlement or expenses, joint or several, (collectively, “Subscriber Claims”) reasonably incurred in investigating, preparing or defending any action, claim, suit, inquiry, proceeding, investigation or appeal taken from the foregoing by or before any court or governmental, administrative or other regulatory agency, body or the SEC, whether pending or threatened, whether or not an indemnified party is or may be a party thereto, to which any of them may become subject insofar as such Subscriber Claims (or actions or proceedings, whether commenced or threatened, in respect thereof) arise out of or are based upon: (i) any blue sky application or other document executed by the Company specifically for that purpose or based upon written information furnished by the Company filed in any state or other jurisdiction in order to qualify any or all of the Notes (or securities issuable upon conversion of the Notes) under the securities laws thereof (any such application, document or information herein called a “Blue Sky Application”); (ii) any untrue statement or alleged untrue statement of a material fact made by the Company in this Agreement; (iii) arise out of or are based upon any breach by the Company of any representation, warranty, or agreement made by it contained herein or in the Note; or (iv) any violation by the Company or its agents of any rule or regulation promulgated under the Securities Act applicable to the Company or its agents and relating to action or inaction required of the Company in connection with such registration; and will reimburse such Subscriber, and each such officer, director or member and each such controlling person for any legal or other expenses reasonably incurred by them in connection with investigating or defending any such Claim or action; provided, however, that the Company will not be liable in any such case if and to the extent that any such loss, claim, damage or liability arises out of or is based upon an untrue statement or alleged untrue statement or omission or alleged omission so made in conformity with information furnished by such Subscriber or any such controlling person to the Company.

 

6

 

 

3.02 Addresses and Notices. All notices, demands, consents, requests, instructions and other communications to be given or delivered or permitted under or by reason of the provisions of this Agreement or in connection with the transactions contemplated hereby shall be in writing and shall be deemed to be delivered and received by the intended recipient as follows: (i) if personally delivered, on the business day of such delivery (as evidenced by the receipt of the personal delivery service), (ii) if mailed certified or registered mail return receipt requested, two (2) business days after being mailed, or (iii) if delivered by overnight courier (with all charges having been prepaid), on the business day of such delivery (as evidenced by the receipt of the overnight courier service of recognized standing). If any notice, demand, consent, request, instruction or other communication cannot be delivered because of a changed address of which no notice was given (in accordance with this Section 3.02, or the refusal to accept same, the notice, demand, consent, request, instruction or other communication shall be deemed received on the second business day the notice is sent (as evidenced by a sworn affidavit of the sender). All such notices, demands, consents, requests, instructions and other communications will be sent to the following addresses or facsimile numbers as applicable:

 

If to the Company to:

Biotricity Inc.

203 Redwood Shores Parkway, Suite 600

Redwood City, California 94065

Attention: Waqaas Al-Siddiq

   
With a copy (which shall not
constitute notice) to:

Sichenzia Ross Ference LLP

1185 Avenue of the Americas, 37th Floor

New York, New York 10036

Attention: David B. Manno, Esq.

Facsimile: (212) 930-9725

 

If to the Subscriber, to the address set forth on the signature page annexed hereto.

 

Any such person may by notice given in accordance with this Section 3.02 to the other parties hereto designate another address or person for receipt by such person of notices hereunder.

 

3.03 Titles and Captions. All Article and Section titles or captions in this Agreement are for convenience only. They shall not be deemed part of this Agreement and do not in any way define, limit, extend or describe the scope or intent of any provisions hereof.

 

3.04 Assignability. This Agreement is not transferable or assignable by the undersigned.

 

3.05 Pronouns and Plurals. Whenever the context may require, any pronoun used herein shall include the corresponding masculine, feminine or neuter forms. The singular form of nouns, pronouns and verbs shall include the plural and vice versa.

 

3.06 Further Action. The parties shall execute and deliver all documents, provide all information and take or forbear from taking all such action as may be necessary or appropriate to achieve the purposes of this Agreement. Each party shall bear its own expenses in connection therewith.

 

3.07 Applicable Law. This Agreement shall be construed in accordance with and governed by the laws of the State of New York without regard to its conflict of law rules.

 

3.08 Binding Effect. This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective heirs, administrators, successors, legal representatives, personal representatives, permitted transferees and permitted assigns. If the undersigned is more than one person, the obligation of the undersigned shall be joint and several and the agreements, representations, warranties and acknowledgments herein contained shall be deemed to be made by and be binding upon each such person and such person’s heirs, executors, administrators and successors.

 

7

 

 

3.09 Integration. This Agreement, together with the remainder of the Subscription Documents of which this Agreement forms a part, constitutes the entire agreement among the parties pertaining to the subject matter hereof and supersedes and replaces all prior and contemporaneous agreements and understandings, whether written or oral, pertaining thereto. No covenant, representation or condition not expressed in this Agreement shall affect or be deemed to interpret, change or restrict the express provisions hereof.

 

3.10 Amendment. This Agreement may be modified or amended only with the written approval of all parties.

 

3.11 Creditors. None of the provisions of this Agreement shall be for the benefit of or enforceable by creditors of any party.

 

3.12 Waiver. No failure by any party to insist upon the strict performance of any covenant, agreement, term or condition of this Agreement or to exercise any right or remedy available upon a breach thereof shall constitute a waiver of any such breach or of such or any other covenant, agreement, term or condition.

 

3.13 Rights and Remedies. The rights and remedies of each of the parties hereunder shall be mutually exclusive, and the implementation of one or more of the provisions of this Agreement shall not preclude the implementation of any other provision.

 

3.14 Counterparts. This Agreement may be executed in one or more counterparts, each of which will be deemed to be an original copy of this Agreement and all of which, when taken together, will be deemed to constitute one and the same agreement. In the event that any signature is delivered by facsimile transmission or by e-mail delivery of a “.pdf” format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or “.pdf” signature page were an original thereof.

 

[Remainder of the Page Intentionally Blank]

 

8

 

 

IN WITNESS WHEREOF, the undersigned has executed this Agreement on this 31_ day of Oct ,

2023.

 

Signature of Subscriber:    
              
By:     Print Name of Subscriber
Name:      
Title:      

 

     
_ Social Security Number(s) or EIN    
     
Mailing Address of Subscriber(s)   Residence of Subscriber(s)
     
_ Street   Street
     
City         State         Zip Code   City         State         Zip Code

 

If Joint Ownership, check one:

 

Joint Tenants with Right of Survivorship
Tenants-in-Common
Tenants by the Entirety
Community Property
Other (specify): __________________

 

  $ 1,000,000
  Aggregate Subscription Amount
   
  Method of Payment: ☐ Wire Transfer ☒ Check

 

FOREGOING SUBSCRIPTION ACCEPTED:  
     
BIOTRICITY INC.  
     
By:    
Name: Waqaas Alsiddiq  
Title: CEO  

 

9

EX-101.SCH 4 btcy-20231031.xsd INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 btcy-20231031_lab.xml INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 btcy-20231031_pre.xml INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover
Oct. 31, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Oct. 31, 2023
Entity File Number 001-40761
Entity Registrant Name BIOTRICITY INC.
Entity Central Index Key 0001630113
Entity Tax Identification Number 30-0983531
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 203 Redwood Shores Parkway
Entity Address, Address Line Two Suite 600
Entity Address, City or Town Redwood City
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94065
City Area Code (650)
Local Phone Number 832-1626
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, Par Value $0.001
Trading Symbol BTCY
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001630113 2023-10-31 2023-10-31 iso4217:USD shares iso4217:USD shares false 0001630113 8-K 2023-10-31 BIOTRICITY INC. NV 001-40761 30-0983531 203 Redwood Shores Parkway Suite 600 Redwood City CA 94065 (650) 832-1626 false false false false Common Stock, Par Value $0.001 BTCY NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://biotricity.com/role/Cover Cover Cover 1 false false All Reports Book All Reports btcy-20231031.xsd btcy-20231031_lab.xml btcy-20231031_pre.xml form8-k.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form8-k.htm": { "nsprefix": "BTCY", "nsuri": "http://biotricity.com/20231031", "dts": { "schema": { "local": [ "btcy-20231031.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "btcy-20231031_lab.xml" ] }, "presentationLink": { "local": [ "btcy-20231031_pre.xml" ] }, "inline": { "local": [ "form8-k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://biotricity.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-10-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-10-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://biotricity.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001493152-23-039557-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-039557-xbrl.zip M4$L#!!0 ( /"&9E?2TR,#(S,3 S,2YX M],_T'UNV\P20.!9!K2M,R0-@T)2?O2D6T!&H3D2#*7?'TE MVS(7 P':\B3OGG-VU[LKT[BY0REC477"4\9%P M0C;>3[ KH4Q$H>;-O/RW'_T6B[ @UTYO8_%Q=H^?!XB>)=>03L43?&E_">YJ MKR>_SBIH-)P\7;T&/0H?YB/YX^5F\KF%PXK+GMH][VL6LB'"(1I#H)I!1=/2 M]>7E3:L.XP.WXGF^^WS;Z:8X*P/69P33T2:X7ZO5W-1KH"7D+.#$2%==[0Z@ M0(6R\N(=>$R%A#1R("R#3]S,N0+%&Z&G&10;:(36< *%SH!-7.50^$K5 M !-A#R","W ?BB 5S1TK8,%E&:B,ZR!;SF,D-D(SUPKAZJ'UL\ &F$F.0RSG M>BI3G.]5?;5;!(T1E3>,CZ]1'R9$I?*20(+[&$46D) /D-1C)F(8HC?US+1" M2ID::K59N47;XABKJ2T,RJ2[7.>,H >5/M 'M57;@FBWVV+J;K CII6=ER2 M,X(1ZF.*T^#Y'OG UEN3Z%+5,64VW'5P62D1*/I.+])SS)%0]+2HCC+D_!RR MFQM"$B;D*.HBOUW,W&Y>9>D=FW6Z1WV0KF%=#TS3$EA?A%9N&W+4;UJ!#.>V MZ>AO5;:C!LI =(0=:YCV:/U-Y8&-!.1A2:5T32@1%B,NL9KJI;L@2QU+3;]; M"@-T'&$!]Q]63F!P:.6*@LA_++FC]DL3B#1R6A.$=D<26&WU3?+$-K@_I M".T;=,N786?0C1P7$2F,Y>@4EK\C?Y%#*G-0$BOMC"1WM806K=BJC_I3M2V= MMYCILSAJ"$*64,GGAPS",L4\'->-Q3^ _1IA\%D3])^"8\,>,07EX)M&H.%F M:NKX!U!+ P04 " #PAF9718/B,?T* " A@ %0 &)T8WDM,C R,S$P M,S%?;&%B+GAM;,V=76_CN!6&[POT/W#=FQ88QXF#%DAV9A<93[(P-IMD8\]L MVT6QH"7&$4*3 24G]K\O*8FR1/%(2HJ2G(L9C_@>ZJ7XF*2^CC_^N-M0]$)$ MFG#V:71R=#Q"A$4\3MCZT^CK8GRQF,WG(Y1FF,683U]?7(\9?\"L73^E1 MQ#?#*EQD.-NF56W'N^/R3Q'^D2;LZ5S]M<(I0?)XL?1\ER:?1FJ_Y6Y?3X^X M6$^FQ\U=\PAG>;?W[@:!"O6_L9:-U:;QR71\>G*T2^.1/OCY M$12[&:H$!,5/V%DC3,2JQV=J1V=_$/M MZ"_EYFN\(G2$E%+R ;;KK%%7&31Q;?:.B(3'E^Q]KLUH3_;E=T=D_T,#ZO'. MF[#D&:;O,E^/=&[[AKSOB!_BW!]I.FYVQ,B\-8A#\(OK'NMFPUMQ3^05=5?'%8Y"X HPV9("G?BHB\J5?J M;J&C5#K:4*E02RK"QE\7HQ]R#?I=J_[S<7*HQ4%'RR70=D-8MI0U6EK0+';5 MS393NI?K94%TLL60V<=:@I3&<0=?R!W':N=7%*\M]HUR5UULM:7[N%$81"?; M')F]7&F0$OGJYB\DC43RK);S7>UHR)QWNL5DJ^]KFK 0:!N#2:AI/0WL]V2= MJ*E%65#GMT1M[!C& +WKH;_3MCD76,5!0#/$(3A;U(-0%>6)HPO&MIC>DVR$P>@&5/L$XRI)(TP++U=R6]K1/(O6-2"@71.2 MEC H4"!W("Q%@&8F#_$*S+\(%L-PJ2G]P-*R:D>ED@4(BNFM#Q.E]P+);"M$ MPS4\X\!29S=E>\Q6]V>UW<)6*8>8@2;8\K<$F WV:2@J0F( M!*LQ@(:#-G^FU L1,SDR"4SG+":[G\D>;%=+YY8)P&83"D,4$!5V9P 6I1CE M:B3E7L"X$\D&B_TBB7JFBK;0+1J0T28;IBH@. !K !VE&BWF,Y\SR1+OYK$$ M-7E(BN?!>R@!]6YAZ;'=9 80!X1.MT. (!F$FE$^09JSB(MG7GO<8<:W<@#< MSW@,KU!ZHMQ"-:@)3;0Z0P(";(A/ +-&Z(?BF13$U7L\>05(U>"%N(LXE@^H?F="@TIT%#<_HN:&3'>QUK9O+CK5CR5]O# MV:#2"S)MJU9@#K+P<&EYZX-%!:CUC KQB4F^L+H5=X*_)"R"E\R0W LP@&DK M-88V/'3L!OOXJ1;$.L[K6%,LRGN_)%KF9Y1IFK0/,84F/$B:QGH'ET+M$XD[ MGF:8_CMY[CP1MXN]X&$U;(6DH0P/%9N]/F"*&"2#?)Q8E[BJ&QK65\F,O M %ML'5X!KA4& 8'-4?L5X.+J22%RWULC"ZN&VH MUO?(&?R 0%OBJJAPP9?9Z+D.YSM/5>)5A M(K4/W[4R9S.[::>:R'5!$+UKNFE-T[K<<6_^)I),[GG&-YLM*^_RV)X;!'2N M>KG3INYQJRB(WN]R9I)0:E%3[!B+!:=)E&0)6_\B3SY%@FVMLHE< 0$;U#2T M%4&@ -HR.3@(D58ZAN!.$ 4AD1V1OP2H$@N)VX<'ZVS?)78%1;]A#0>L# *2 M7GLF+#)@'-4B4!&"\AB_V,S3=$O$F^"QA'A""#0/@-32AX@39+(7JB+0)UL+ M$FWE_+@_F:Z6249M)Y=MB;,Y"3!7S4A&>1!L *9,%O(RQ!_0R?2OJ[\A'>6X M^V_X4F"5/':QWZPX!;)/656N(.BPJ#FP2() ?9ETG##42E%A=9'=JJ&64MS MC')7 %AMZ:YO% ;1Z39'K2]_HZ\]#?F7N^A1FB+ "PEVF>NAWV;2'/[KFB 0 MZ##6.BDII4AK?;R0<)BRUOV+@+6W1<"Z9Q&P#G$1L!ZZ"%A[6P3HW18I0N2X M=+NBR1H#R0D[U:ZAZ+!L\F&1!H4*[ \<,ZH0=(AQG=$R3W&FTO.+3;[_*_G! MTDI YRRG99?-*JFE310$(UW.6FDMBZ1S-3%2:M=<;.,D(W%AYBIAF$4)IE5Z M1-L5\?X09[0,-%^!TZ,/@Z%A)ELX%6$ZEV$5>$AUZ?I2>O$ QF^$TI\9?V4+ M@E/.2%Q<2['=*>K6NWUBIL=V\Z$90!P$3D,< H_.J*#QDXI".JR\$N:%I&^< M;EF&1?XNN;"-3(#.+3F S28QAB@@4NS. $(J,2K4?E[0+K)'5(NLXG>'P 9" MO:W>:-M[:MFH#8J;3(/0.=YGSX[ V+J(\O6*9$?5[$<=3XH;*?>*8EL5V M[IA*$A >-E\=&60$TEHO+"PVF-+/VS1A)(4G(D/EE@6KQ28+#4E +-A\ 2SD M4J2U7EBXW!"QEM/;3X*_9H]E?E:P;8#:+1N=EIN,6*4!L=+E#V!&AZ B1J?4 M]0//[I!0O,BR"+?4(G6,#6C68*:E"PD8R%R+%DHB=;WEAF=HR='7E*#LD:#+ M\F?HZIG@BWI\_=)(%*D7(HI5.8NQL"'4)7;^JR.@X=9OC[2408#4:P_^'9(J M ND0Q]3<2H9%_3PN-S'/R 9\VZ$_Q!5!0\UKCOKT0= TT*3)5![6/+G. Y&* M])G-J)[<'E[B-42.5\86@\;"N*8(@A'0%K0LKO]6@)_<>=L53:(KRC%\E:6A M<9PQKVW/2)9W$ 1$0-L5E"(O%Z)3+7&Q@$A&]U"YWJI:A> M 5JI9\3**M#OJA*4UV+[_?+ZIFOY26[6F^1?*YP2N>6_4$L#!!0 ( /"& M9E<6VWJG5@< -E7 5 8G1C>2TR,#(S,3 S,5]P&ULS9S+D[L.I:UL5-6SMV,[9B931Q8M=RDK:;#$1"$L8@H % 2WK[ J2HZ$* MQQL>>V'+U(_+_QT2Y"$!7KQ;I3QZIDHS*2Y;O9-N*Z(BE@D3L\O6EW'[:CP8 MC5J1-D0DA$M!+UM"MM[]]?-/D?VY^*7=CH:,\N0\>B_C]DA,Y=OH,TGI>?2! M"JJ(D>IM])7PS&V10\:IB@8R77!JJ/VB:/@\>G/2[TZB=AM0[UCS3F>Y7)X(^4R64CWIDUBFL K'AIA,;VOKKKJ;GZ+X!6?BZ=S]FA!- M(\M+Z/.59I7IB52S3K_;[77^^70[CN8MLI2KI:J:G>N\>[VTSD5?A_FN7 MLK;;U.[UVZ>]DY5.6B7\G*"2G#[0:>3^VNAM6YTP:12+F5F[D'7<*[H]+(U,?':UM\_[76+VG_=$YGUPNZ:FKD]JQ5U]EI>**JI,+G96[MA MKPA=&;M#T:2LR+4/[YMAQLDW.TPO:KN]*TMM:_9CH=QTI>P,E_%>^]Q%01Z8 M+??HG+6F\\%ZWCGW"@Z"Z)L1>UXSO@V MSE,E4Q^=#0GIZ>@N*-M$,S2O;/N)Z\.0DUDUS@,)D&&L9<'CL/=,9#\J(C1S M?"# C]5 XK^C7GAX/"(A'\\IYRZ-(P*TEU?I@=C_P,3N]_D*P-\\N_.[/;7 MV>\4 >+_\[7@/W*+%(%[JIA,["E= =@?B8'4SS"I>QRB\KX1"93V5@K.?_!A M']A#0CUD.B:\Z-'0;M-AW!5R*'*4G+/6)BKV?RE18.@[8BARE#2TQF+#P >9 M4GN="8XJ?C44.4H"6F>R8>8WPC"S=O?]/V?IY,>-TWW6QRHH8Y2DTV<*A6UY MIT$8]S@CQ/=0"66,DFN&S*%P'E@_BO"12.CJ(UV'0!])H:11_+EE@O9"H:B4@Y\1 MX04@8/.58.^_#'L?CATE#ZVU^4JPG[X,^RD<.THN6FL3$_O ?KQ3CW+I>0+M M%4.1H^2B-18Q@>=GFCMUK^0S*^9%U5$_*@%%CYBBALVB[O#%21ZRMY=**&_$ M=+7:'";G>ZD-X?^Q1=V59+4>RAPQ<0T9;?H&8Q%W=]/"-Y7H0 +EBY*K5MII M&JF+L*+$O_ON*Z! 41+0*C,-\[R5[MG'7(K@_=AC%90K2B;I,]7TP.NF$FOO MH;_S-7@&&\JP>FBC88S?%#.V!P.9IIG8W*/Q/!7S2*%X4=*_H+V&48\E=[/; MF9A]LE>(BA%>S;E*!X6,DNSYC35,^%Y1%VEJ+[OS>5QNK8&ZFTY](V](#R6. MDNO5&\4E/](ZH^JE_"M*0:. DO9!33<]SM XL\/>NM>?/+H5,YY1YD@%98V2 M\OE,-3^Y2&50BAAE 0O8*UAR'O]J,9[((&"168IJ7PBJ/(< QXI%#GBLT.//9RYE\6DYNVYIWAE M1XBXKP04/.)#Q+!9I/EIAKH^LV?ZGABRZ6&(OZ\$E#_B \6P6;3Y\VI@3SPS M&7YF?B"$TD:<"EMI#07R."6<7V>:":J#8\N!$ H9< E#HB#-;@U9QX*]^K",OUK\%R5>HP6\G0,3N-8GUVHTX=A,I MBC.Y2(CR4 _IH=Q1%U;ZC39,_L[,J=J]?LH[,[)Y6VC20WTI:!10TE6H:9QS MZ\Y*_N"I=4\'Y8V8F%89PUDSE4TXBX=D?"[UHMW>#>45M\XWZY][#:+?\#4$L#!!0 ( /"&9E?0[8N, M]"X !=8 0 * 97@Q,"TQ+FAT;>U]:U,;2=;F=T7H/^3ZW;<#(F0W^#HV M'D?(6)YFUPT,X''T;FQ,I%0IR*94I:X+F/GU>VZ9E74!@PVV+#01,V,D559> MSCEYKL]Y_=O1[Q_>]'NO?QL-W\'_*_S/ZZ.=HP^C-Z]_Y?^';W^5KU^_W7OW MASH\^N/#Z.\/IFE2O%*;&_-"'=F9R=6N.5<'Z4PG _Y@H Y-9JWN<31YQ,[MD6_M[GQ:'.15OJ3G&;'DEK+_HYK?/WQS>''MX?;!SO[ M1SM[N_W>\!\'H]'OH]VCU[]^?/.%M7^OH_VSS L[O;C5=;_UQ_MVP98I']HD M,OCVC4?/;'*;2S_Z;>>PWPM/7?E#5VO%BL1VGN4V.^[UW,$;XGH$:7RB=1&ILBG-C$@4_?KNS=W2PL[US](?:V=U^ MA#\?* W+/].1A@ED\S33A4V3UEO2V5PG%_7Q<7":9SG.)YD=FZS?L[CO=FIA M%>D-5G'HAPA?\6BQ:&OAQ>./E(4'(R"KX8?#Y3VR>RSU8.F??AL=C(:')#+Z M/>1>D0DJ-^8T5\#3N8EC^#0Y,UEAQ[%1^YF9FBP#6;";%O!"D6O3-)N!\$C, M9_A&Y '(0KA-13]2;_'^;,H('".0#BA^^KU)&L=F4M@S$U\H_SH>L/UX7A=@ M\S++2YT4^/M#' 5$UM,UO;[V>-U)9OBXS&QA8?;#28&?;KY\\F2 PVN0[!&\ M#*?9[P6RK/9(3?2CQ#PH86>>;3Q?&]-+#LQQ&;/,?:?6JE'"S^MCY&J>I;,R M/J9+I(0Y9(VI@B("G27H>F^C81/2LO[F< ANPAWL&YX9T/X7[ M)3W/7RW6:?]4U/P=E=#AP='.]H=1O[>S'.L!E6C_X\'V;\-#6-/>>[6]M_NO M$:SQ[8>1V@%R>QSNH\C=?+2QB4JQ2*,-7# M>C(Q<_*]X*V!WY.Q )L7W OWW>VP?'ST&/EH7U\@,?1[[T'3:#&5:O 4$0?: MD+H(=820HEGIK=0)U& "UG$6I!_SERQ'ZJ_3?;]G21L?@\X$:HPJY\@+Y7AF M\]SK4S5B#JUH4-3C,O(NP[PQSW?II,1G0" !R"KVD1/X9)2D9FB,G;O76S+ M1^M/D-:/3#;+^SV4ZPST>.0 '#PA/P4!]!P M:21G)B]"EI$1!\1S^/Q$S\F^@ <,&1L%S(_M%]A@8!O<0!PR_]*8M T\*/Q, M+L+A9)*9B):X0P^FV#&&<4$F"-Q7'$1;;;\0U]R_*##:8!3 MP8-(4G<.L']PSH_44$TX6@#D"C.>P&-PK4_@*M=UN0'3(?/JC&[8ELVD(Z8H M-/!XP#R8CG,TT4L*?6K4/-83$%@P>54 _9+?-*4BV; MI'J*DHK]Q7C5/<*LB(]OALSLZ3QT)_R6QDA>2,@H$9!XD'+ ZC?5/8Q>@G(V M\WX(K?Y9PJ(H&/4>+KYD@E19TU3#]RN.H'WT6BIJEEE:'I^X%X"T 0&5N4F- MX,\+!6I%"O(,'U:B /R."K(M+NC# ?*>>P1^F1? 0CB1P,V&/ 6RHB3V!X$ MHD)D\X3=Z2@^81*\O:C-9^VEP@67H;'RKT_# M?5;3P!98V]Q8Y_> *8&FQE&FZ6#>Z8MXV?C-(,S]I^]A2OE5&T^>@;;FZ>QC6#E1T/TBVR//GS8'[Y[ MM[/[C[\_V'A ?Q_N#[?=W_)2&0_C1WJ>P^3.]W4]S1S?"A7]U3^,WK7X_>X?\C MP]'NT1 3:P[[O>'N._5I>' PW#W:6;DXET\)?"PNS@,S!YT'WJ&='0 W^R>= M93HALZ9N";3MV,P]SQ;;.3^9NRL[,!S1F%P%.WU6K1:UJG1@])P?0P4^B B"Q9QD69, MVSDJXB>D\.8J 5,YSW7F?8^O2)?7X4Z(KQR=-OU>9&+0=#-6G4'#1R>B1F6A M[6:L\]P6*_>UD0!LI>P7FU)W;EE/(@489^B"X@,J("$RJ<_J *(* _(V'A4PVCKC4* M*'H4X,"PMHW K,"G,"0]+>/X L,IEN,229IH,,W@8&%(?E=M/;CK[;74]MB% MA.B5Z)0Z1@,GLSDY7Y ;YGC.\X(_!C;(R=M'_^KW8/"IS< (S1 9'\<;-&Y)N\-9P8D8KI)"@R M4UW&R IX#5Q(3D! /E78FRDA2=Y2D<<$+[G*)[>PPT7,*E<-\,M*47]F,2 M]J,$1,;$@$$4@[@6:3\$+IFQ![<[_$>Q0\DL(19T8@/9T,<4 YE1>2%1/".7 MN7Q%EEWT;Z90T"R2FGMBT+HV^EA;&++VO:7P*)C%)&B(8?'Z0?]TCA.ED "Y;('E93#V MA.?>DP_S/C:)R4!D@!EJ"WP92#;V=,5XKL"<\*.Q3DZSDYZ@9JCE-"*/>A(];19VS&D.0_1=Q89.2#RPVMM=\C71'F.(WMI* 5$N-78@PFY.[Y-8H9*G.& MI\'Z!,D>6 2ZH5.4 ?.VTA&*-H,F$5,=YP:4N4W )AIXN@7#B2-*'"[BD#1) MJ[FP;U,RX9?\TO!U%-"65ZJ_2I/SH_@<*5@4ZVE?')+JX"4!ALQ9X O7??%& MD&@A9UTTDQYJ_@>:^U02!JHWD@BY@2.B_F)V270882*@\&=Y.>;\CU0J ](S MFWOMDK>4Y- Y7%4H"_\LDPD+J [))(_ B6=%G5I@4:0 UD2H1M7^^U,)[4EF M>#?\*\5;,X MP956M,USQNP.X2 2LS7MOXMH2=0^O*I,N@[<2)F1-T9GDK4$O4(FK6?&K[]>) M9BGGTXSH*@+QA3D!H$S.R@2T)Q8,L%WFF.W.!A_B**RJH4,SS2AW069*'-Y8 MB,0G8E:[TESRCDVUNH%HM#*JR'SQ/5SSQ/J]UI&1% G/K-+G.\[&"77^GGU\ M\'NLZ2[NG3U]=:[#XU5:P]VF-3Q>I34L.HQT;G!.)\"S5(7?,/V M>T:C,HSE.H%JCFIJFA7'0'F@F5*E(][,!A9(PPQ @$_*V3AC'UBF)B>PP?!Q MX+G&("K8IRQJS]C[,H'>N".@=OSPA3.]X+.MH02,;>4T PX<2ME^YV"F'1=IQCD$QCJ"QQ.=X@4\&&R%AA)U<4Z/ARN;CB!_.F6F$<+PGPKX?*MPN58]'Q7 M4N C1VWYTBHM" H1)BY6SH4%2'%"MS.C$[)0IZHJ-:@2]:LW^_<,D;4(Y.+I M1@AR48']H"=2ZB*\-])S6%")@+\8?09! \HY#N_JF0H?OK]OZN32T_.)#\\< M@NHZD6@&$_.NL7+75$2=B M-[ R*L&)"/-T]::V\QB>"2!:"$/B7/%W]'E[, ME0&);Q,&[P%K088Y+1#R+N2TU1-+<;HU7LL\7S'.D1 /A0=#'* F(:8 M_FKDZ?PAG2([H-U^[S+B[2@7'"CV"8C/DIA4JLJXB(-*OMA3S;D_ L54+SKD MTC10DDGUHUB15\!"^ZHTA$;(H!;&#SV"% TN,/!VP5%A+M+U3%^1 M.-FKR*>2&N1S!X)@F%Q$#>/4Q8-S%Z*N1ZC1IP+D[(,Y"1EN6+1591]],?HM M>4#>ZOGR9*IP-!EL["P-I,@8,T#F%*3&MY-!I[W9U>])P$B@)9Q^(0ED'>$W M.2^:3YA^ZD1E>'PK9EXR9CY=YR"@5(JKB3VS1Z-^&$SN,ACP65DBH*\\@DG#E4E MB1[?JETZ[T+T@ZX(_,#QWS2(@/O;..KB,91OES*9NBT>JVS$6BRV<0H8=_G> MQZ#:IT""]L;'X'-J7%ICMUC&*F<;69BW@)$,+CNM0;]W0YEXR7&%V6^M*:Q1 M CQY!AC_8=T=$9;NPQD%%942D \D(R /4P9(UH.D+V+)I_@: M.=]>4_T&NNZB%DO@W3N!?OMU9H\92BL[LV6$K@S ML30:-9&MY 8.ST1F0&XZ>JAFL'A*IJ1>@JXHTGYO!I)T("5KL>1SN;^PB&!. MWK;8Z?]V1N:*).&&E9SRF3#:!=W&?QJYW346>LS]+3VS&.-R6*-P$:9ST GP MRPQ#5.C"]G>\E!>@W>YR1BC'T7*>JV#:=KE MUTN V1$&<"A_+I),EGMN0UR=7?%DE5UQM]D53U;9%8O.(E GIJK$_)SK'TLJ LHK M>"Z&-0P"[O,RPPQ.>"21^@%4ECC3 S-3*4?;>4&1*#%H$J&/PHY+*5"N= +X M D=K%)Q+S(0R?1!';VPZ(1?OF]*P]*0\;I,R:N,G&G5XT.@1&BZSY/Q(Y_,T M*\J$X2H8^4$B4&$N]@01'K/$\8%#9PRKZ .Z:QB:0,SBCJ>49P65SN%L.5E*.KTX'%/'*AYH M4O X9/$<>JP@*FN)Z3EQ$SF-J"*\%FT\PU/AVT8C.*9T%,"_@T%H*O5.7>W2 MH+;.OV+5)6/52?>MDZ@NV-=+TK*ND3 5] 0Z'&W7T-L#G-A^+XS\,[.=N#26 MRC'-##R')9&V#Q.JJJ,(1\#Q-)!Z@0S*R9'D@+\.6&Z_Y]%RQ9G.U4XUTYCD M15QGS"Z0WQ-N=<061-5IA,]3/##PSQS=T TW"P5Y,_3BB^<]W!"_\+:_IM5 A;W: M2?-W_Q3QFVA+Q674<(O1=UH=MX;4<0L5G4J[F?)*+W#/2;MY;R+*F:(##'(I MT)D29E1@VL1*W"V9N(O643RU?5J(M1J3=H#Z*5( Z@9M)V-:%P(=O(Y:=&1T M['1I-<[24Z;W-I(0PHJXSA6U/"COZI0BR&XI!3?&'W3+^0IFB3%:\L&:^83M6 JPY9 MGEZ9BP/OT,<"+^$I$\OP@&S2"T-08G7_-*4&,2A08*BBL:L_D[Y:M<]"*CU# MP!U_93@^&J -#*\ZL7/A@]Q?G# S8J_6G8>,FR%N?X0NU> RT]$9Q]@I4^$$ M\>ZI3CUVE9QDT&8PZ70*J]_JQN<0FMGG@U%P!7S*(; .SV0.;T6DTBSB<6;=8H6A.]Y@8P6#23 2XD?=,%P[U.*/)$1 ?\\N9CC13VA MNP9U.]<%K\L#%5'%=";E6I2)+J!?':MA00GRC>6K0 M-RK\75>S:5TP)@,6V+'^3.X([]<#D:@Q]5&B>F3]5+O_".PQ[QEHJ2!??9#P MS45X? ,/B-COD9,!A!Q,DG;TRJX=DJ6,>LD5VC42AR0J,SR:3,XE*U<%W'_" M(WED)P+^2;:+)R+8*M2&RH04'%H#IO#D:3A=FE3,\J^9U,P_$Z DM'S/M(TK MR,KNG:W,H"JKB^$QL$N(>$SY]5^]_RNINV12][A3G4+V=]X_AW;5;@A405%< MKX\/MS BNV&*""L$3VO3R.&/=73?(PU(1TV+WQ6N"F)..^E[P>BT<8XO-A^] M?$;!VA^9!_!TE0=PMWD 3U=Y "OY_N,+1YOR?:8MQ5CRR\*U$4IWBZB(Y,.1 MA#5#[E3-'A?K;&!06]*,4&X,&I$4X"V2T#+TR5I+Z=7OOM*$QL]QGW9%SY#C#H#ZO/$G.15UH+U2U9 M2NK%E.%:_.&J,&\5U\#DS GCDS92%$EQK:)W;F1W9L23UZ3)PN;BH-6,H^R*BL@-P@9'#4Q.S[,!$(IU,^=RN'0;+ N/GJZKG6FK8SNG33#(8,LM9Z5K@J"/H_?2=6_P MJ4@2_R84+=]?LW*U.<\87DFA3XS\A+:.?5Z'.>]*Q.L,@3"DP5\E, >Z#+H[ M"A%@9:V\>4!%$Q.=910WN1PU,H");$(#^]+R<.?F/MV!8C$!9' %V\Z[YM!V MZCN^H.E%(W*,+1G@-K5Z,=9Z96,XMR%7I[$->2U_I1KUB/R6B&O.NE,4U M8JAU?/W:"34[H:.3\\K&&1Y1/\PQZ6J>82_SC","6;-KAJDU+!%2"OMF!"[? MH#L&9I.Z]A@#1'E#9&!;SK"T)234\.9 @JK$&,'$P7S[Z:^,>7'HREZ"@5=<5R@$@#]\^A;8-@1)\$I\.&\4&/'K# M#A&7$T^[994/-EQ.H75-NCEF%];#H-X]@4$>*@@&WSOA_,20JJ&G!6K%^)9C M>R;)9:R0#+K[)ZP'T0:'X4#2KXWAT"&1+T=QL$@I@MB K$:0#0,7X/;N4">. M+^TIL6:GU:6PSNTC=)E+22764X<]$L#4KT)7#'.(>!?208J/5";5H@W1GKYE MY]75&P\'T][Y07M#JG8/52X?OI^:/[@4 ?0\NJ@ZJUZ<$4Q1F!D'\D2?\_CB M8DK6T/D%<;W=+:*Q,X3^@9GTILK6K=FV%ZZ\QW "'% M,"4T'EB\CMW*Z[/S]Z97IXL3FT6.[@H/7!FB_DPE02W-OAPVVZ+2_35[MEZU M_!#4Y8H%?#.11@.U +2_:B/2U1UDCE\7'B>;#JW6G:\.E'(M+G- *"L+=LFT MX[CM?&JEE+K4MDL: PR<>3LMT>=#VF*F"=*TRHB?EM)"P'R>NPPXKW:Z!AE4 MR((5 N;R'D6)H;+?5S0B:B? (GIN(QX8Q=H6?Q6\G(/W*!4P$1ES^K%-WQ;( M[A.2VW0K,'8K&>O33'L7UE:_=T*YK-5P#!Z8F'B+\J%2UYIS-H>7$"0(*M$Y MOP.Y;\*RC)UH)&U "W"K9SD1% 68R4F2QNFQ77427#IVFWT#NY'2QIHINF- ME8L]T(?SZN4K6EXR6DZ^%+= HS>S:9E?+P^BJB !,]P06HGR/O?F:&JJ.5\Z M,OQRK!OKQF]UCY$W="+Z81X6HXW+@JPA9QH+'OKFQC^9(S](]^K MK7(D[C9'XMDJ1^):[, ;'L[MN[_Z]AAQ>'"TL_UAU._M[.S=V@JJT#6V=FL,P /LSA8>IU0W^ASRNA?X5@8&>XO*H BFTSCFAU M ]_Y, UY52D)91"&>005%"<2Z1F,E:.7CN,SEGNH)>B"@*N>_@S *[$9 $[4 M)#J6WU)#'7HH)^?UU?V=V3%+OQU4V)9P/#X#R,5>IFZQ/#!H[9&9DB>QLA1E M15@D,<-D(M"NM:6 :(6F2=YQ]+?0-M 1,]PFG?Z@$PBQ%^E,%BP M5,7N8X/M= BZTWNF4;TZ3J4$M=Y9LZ/M**Z\ 2#KW+[XOGNB(4J(5/FJ?:GI'X#( M/$?.&SBABT+")R[ NQ$KXM@YCS@\AQP!RTU2:97. (R4WF ;",OA+%I-$0ZE M.AE#TV++L]@(RZ@[\^]%^V:9+[WBX "):H[/J^Y_XJD&PUZF Z@; MJP#]WDUT .8O;E=05"U-&4.;\<]39J\T%KE94Y"Z(%OJ*6O]WA!10:ZI:JB[ MU#3ZO1NH&NK.- V2P-=7-=HI0[CUWZYLT#2^4MM0MZ=LU(/N-]8VU&TI&W 1 M?(.VH;Z@;+1.[BI] ^CT*Q2.+USHKWQZK@_RUP(@;I]=@HERN6ZM;NTU"&6N M*]8>\X].N=(B7-OH,/]\6F8)Y_DV!N:T5TG^Y?0$/ZUZ5J)-),TCZ(#D4"+B MN YWLD:L597%YG Q(W_3_+@@-J]"0/S0>I ;V8#M53=3&JO(>$-' M<6DM-U81942?\75#!=$6JJD3"I2C.QG)JC[CW:AZ4S16Y-.LZ/+SZFJ[&]!U M^M-U9 #5WR-WK.#WQ5+OD0I[DYRUB23>2:90U"SWZ #&(=(*\\89/%! L>QL M3*U6&^(EN-#I&U$JT(87I8+$&VD5C9_*-4_Y2-)Q<"HI5(SYX9G175Z=5PX? MQ:QK1;6KJ./^8;L,Y:/RTG$+0;@SM)1*V>?_(D5YVY&Y#9"_OF[ER=2#Q^2J0>+>! MQ.>K0.*B<\BB&?2W;,\_D4XX0RYW-@*WODL9O-+T9LC7"W[@6FBQD9JS42HE MHI2UP:EYOB].1^%;SK@3'!CU(.=>5;]X@9>I2$ W1H&X. MNS>^J'J85,B%O!W^BPA?$LD*:D4Q#LK8J_F<@$DEIQ,[I]ISC66R<9R>YVR> MP*7,UY#FCOOI6G,O?/.C5\]E9L, M@=C 9BMMI2P8])'S5*T]7J_- M-I<\>&YDS"]PW2/YI=7FH:V,)C%E4*.=;.'!-8XVP:Z+@P.3Z\BRQL(/LNIM MM#[PA?GAR]57[51[#K)3^ /L&W-,U6:^GFR=JUY\NCOJG*Z]'+.&YXP:8U1Z M9;T>M$)B"K;&<(T#63:"XN61">!#-LZ3U&7\FN&JDJ1>J5ZXV>K0WQTNK\E"GET3KV,D(5: M)ZE5?IX"96K0_",@$7^>.7)?MOZHWT/Y1?1PFT+,I6+F)O%9G@:][= M0GZ0 B4:_*UMXUN;8EV5Q8I4=8/_["23NE5)^[PDF_)XXPDOZ,!$YUAM?7@" M9D@.)DYV>JXOX,$2ZY^?;VPL[1;(RGE1VU2QOHTN6KB4K%8OGVX\?W;%VK^% MRWZ\S!\6TMGF%:_KD_Y+P]4VC!\>VBBR?P4+KPS:A17 =W@;WJZ O=N)WI]# M^@1*,4\-M.MT?H%5O*A0LZZ*VOCKM[@5U-+2%F7AU-'U.[P]E^?&/(2]-,E_ MK+[9A7F0@OK_'NP?M%M 3US:FV-S\V_/>$5#L-A*7Q$VQ/XI$PU//GF!73;B M-,V6=A/@E[R@/]+L=$ /XK_0J?KD^=*NNGEQO@/+-5)O'ZG?T0LP4*/\KZN4 MQI];:WCO[&%9_-KCS\:0C&'2$W.K$WI7^1XER5^Q:X6Z+U#7UBB<1D*<'(HXBP._,R;^;KCV]" MAR9UK1)"D@P_3TLEGH".GB!='=DB=O&P;4TH34% ;,@PC^0@=A18T!,,331WC6F:\2G,*IHR M] T0-O?=P\:Q!$EU$=@>E:\<:9CB/QUMWB)R_KN$CW.-<23,$AUPUN> 4STB M#K2QK&5I"@:/=(XM@K[W06B-$[\6C+CO^O#O*<%3X^TA)4E+L@]1.@*HUBA. M %1=?QGN_YA)>C5CU7'8AL$&J!_-BH*6?LU 0<^0@O:S-,%.62PT]^,RT['( MS$\G)C%GDG%(P??/!=WTDB+HX<]P ,1'\2F1+!$%>T@>SP3;AZ/+^:2,2>1- M$>U6<',34Q(&'N:)29LR!*HM$1&1T#'I*B\Q&U_>RM$^F.,X[WCIG%;#/T&] M!!-I]8JVEW[-0-O/D;;?EQG'M8<37QE-5.4T3"89R2/GNYD#^0RF[I ,!ZZ5 M:ZOG+3>+.R7JA4^I=PW7%NA3"BJ[.+;+M)7NU6,3(%0Y(+UY9E'+I8#^B07. M8R(.FKDV"K74"%-CN0# !>LU)_PB3JU/@JTGUU!Z.*KC*TY8^C4#)[P@/<%G M+O1['_2YXX2:HN#3/B"",KR9)A_$L2>M(F>A5 M$K?!&/24:95&U/ ?"."OS5Q!$E9MX=]YK9:+ 0VJ(L2!U!2T$ Q\?E[7-YP) MZ;5M5Y!7?2-EC92)UM"Z455' $9JL)> A6E\L2,Y1RI,T[3]K-\JKM:C%$@N MU^N$$*_7O>2^\,5!^%@(L[HJ#?/5+=X*E*Y0A8.[&N56%'.*9H4E6?WN$ M,3DM?I_,$(S3$7ZOJ4^LQ@8[;(MRV^#-/>YRHW/)ADG$O=,6?CS#I?BBG^IYA!KN\.I291*[2*^P)E)-"=0A_>F MX*$SDC&YV<#FHBSB3EP3OC*E90,5FP>7)SIU,WBX&$C:N.#6$S(\[RV/O? . MWQ5W?RMW;VZ0T88-MI%RNAV[XD>8I9$O 7$MN3$X47&\H_(:6C_R#_/CBGJ6 MC7HVD7JV70\8H9Y=M">N4XWE%7O7D3TPKZA!1]5&!Q1]WVK&AZ/0';6BJ66C M*2HY_(0=&3-/4&JJ;8QVN#0K$2@2O,MR,-;8ZJ/[G2^Q1I,>!EEQ-VO0<0,; MI^8+() 9@1? )W],!K$R[5BZ"A)_L-'!:$ \A@2@]2137WG/3P M862VLXJ+I_U\G=6%B65F9K/D[C,@3 'WI=C?>L+QQ\@WKEE9)K= M1,ZCT@IJ914T:X]97*IT.>@FMG)2#MT1W MDV" @:=SMB-=^67-7XA^3M@0B_Y4RN?O3)D!_HIC/Q+9;XD@>3D#=] Q?B#9 M<9*.=[!.MA+6C]0.7U*,R5CAJ_C<16Q?Z>I["6O*5X>RGS? 0X$OS4.JOO:% MS%0(+%!*C^;15#"3% <1N6/SE+J@T]U2O59N)X+4@B%:#0^!VUL>8;Z!I4D> M&+$(+87U]-0^=FQ@Q&GS-; Z=YKKET2*'F/PL,VJT5E5T<(_K:*$-QMA.!OJPC!-W/(W74@ M64 %;&>WW_NT<[0[.CQ4GWX;'8SVW@]:(5YLY>05KZ8Y+-[F)YO_=G@JH,_] M\E\OMU"/VX.[._ASL+S2\/'&XR<_3J7XV<$Y6,!>*HCO#HEC>P_7L_OW!X]O M//G;+7]U.BOP3U7H='7=\(^8Z#5JU1=C6M^C,OW&9/[L5L%:;O$L_ R?WL44 MK_^_M[N8)]][N[^DF7X%+L[3%W>\B$5BE%O%X+FX6GK>WEDM*$_?@VGM9Q;3 M&W F: G5+\_[0.1D_\E,%NUP%I1F?III+2O-4JWL2K-=MFG]4.R-E?W[;7+@ M+A37EPMO[#Q>^!G>^28NUB7S[UML4'N83JR.>3+2M>1"[1*F[EJ^CC'3T<[N M3R!7%W1:BT4X]_ %G1:RTH7OVL;4^X#8?!5L.J5O0E2Y2EJY@A;5#;J255^STG^+UE-DQA0_(P']D!!<:[=6HF?!CF@E>A9> M]&S[G@?7#_H)=,<-'O@_=JZVT\C\C!1ZOTYEAK ?H(#X]D)$-R(T#\0 MB79U=HM\=MO<&-%IH_M9BL GJV-;\&/;8S13G-L:(MF!FKG^2OV[]9^%T?Q7 M"N+W<1W<51_*.VV)=E>3_I\\Q\W!QL8&_O<^^'M^FMYUP^-CQ($M).14PQX; MSK!Z?'&/RVWR;>]N,.YB+?@>TN?OICAQG4'!@MS7%S.J^%.B):A/H."J(X%W MY4^?;ZEM=,8LS+7[@QQN2WH7?T-MVIT?Q/N]@]$_]F!KU>''MX?;!SO[1SM[ MNVJXO3W:/QJ]ZT[O_3$"Y]I !S^V2.NFT[R32JTKYQEJ3=_K)"_E@6MNUZU6 M%.WL'1WL;.\<_:%V=K29E<:NL^0"0D84*1"D%:T?[ZZQ> !/62F7+=>G#_B?^'71_;G\Y?=RW>B M/WAWW?KG@U$29\_$R?$L$P,]549TU%STDJF,&_Q%0_15JDE8QP^S9/9,P./%%ZD>3[+J5\,DRY*I_2Y3'[.',M+C^)GX/3>9 M'BT>O#B_ZG8&/B$/1W*JH\6S/Z*"GC7Z/XI'_.#%3_'0S)Z?/\(&8:INOOT@ MZ=DO.<36QXD>ZJQ>>W)TLDT#O1>K>0>#' U>M?OU6J<[:(E7S;Z /\3+5JLC M>JU?V_U!J]>Z%&\ZEZV>&+QJP5_M 7S1'S0'K;[HMR[>]-J#-OS9O!B([I4X M^>7TM"&@F>;K%KQTV1#=GO>Z]\)U\VT?WVAVWG%S\&2]UH6G>N*_X:'^9?MB MT.YVH+7.I7C=?& MMOLM<=GNWW3[^.V5:/WO1>MF(-H=<=%]?7/=;G8N6N)M>_"**+UYT^N_:78& M]=J@"_W"TZW7-TB%N.IU7S=H#+W6O]ZT>RT8WX &T']S\8J'W^._<61'?\ U M7XMA A5G*OV2_'+^LM@7+U_L\BC7C>^_'CX45UI%X3/1RR/U\$:.E7CX\,7Y M9?LWUR\32U0*F6?)"].CLZ@ M%9-$.BS%$;3PPOZ_1\^C"D$[MQIWP7-K!K4R\*\[RI?M[J#7OF@/WM5K[<[% MT=;M,?N=CD.%G9\='ST^FWU1_>+>K/5%M_-;JS=HO[QNU6LWO18?87C*M;9H MV>] X]B.$^2KC6C0A!46%ZWKZ_Y-\Z+=^?6?#XX?T.>;YN6E^_S9H[:'RLGQ M\8_%R1$D421G!NAR?ST@\^U\T/O\#FY5FNE 1HX38'X?6&/P?'#Y^>WY7!6I M458,X>SXQR^\&#>IC@,]DQ&3VYPF.5+YIO_#OT\:Q\?'^+__JZS5X/)+#8VX M[@['UC8F5TSKI5SP?SWF@D?$BB_VPN3K#'/I MK#P^.M/Q5] 7&D)"([#KKV66ISI;T*84!]+0Q.E8CD!S@(=' M.E8A4IZ,%3R?4CL"5D#(($AS%=9KT)S(XYG4H="H;R@#OP MDT#[9B*C2 R53,M')?Q7C/1'F-H4:8#I.'G\(TXX=!/GTX:P38M FHF8 CM- MHL61:'T,%)HJ1AB5U6O T 8/-57 3'.Z=$)OKJ8*IYC[+F<>R3048-OP5). M@._@+UC7($]3%0<+? TGZ4VL<>7[&=!G\,OF%'@[D-2Y:R128Q3D'FZ">HUV M >P&E'$Q:2K#"$6"&BE@N5#$^'OQ"825QFT*#!+ LQ*YFZ74C%B\.4Z5(O8* M)8LFQ['XF78R?%X2$WX+]5K11%5:H'"#@3"W1_H];!:_8^G>@@&#%(O'U*F5 MS<3A^+DB46$OYJG))1 +PYI/-.PW[Z5Z3>-&5N\U-I: * "I#2U!5]#7V J& M?(:__5!(PN6Q=4"&V<''^\F"^W%@N6U?M3AL=ROVE 7W'''"@C: M?L"N; NI6 :H9,&7:%3F$2HE:!JA;>&-89S WHA1.4(3+P>K"^PK[GT,1@7] M%:J93#-6H.HUI$.#54F$#Q.9AO!OD.1I1@.!+6:R-.<6J:FU=DF#J.!)VOQ[ MPJ.D::+&\4N<(/*9P8[,AZ&^U4C,7^K%-5GM9\WZ_IZ'L"@X1?A;. 4I!*.4 M*"Q@2NQ:)ND"&RR>#54 BB<0 =^,:?KH=?(BPK=@W$7P**R14PT#8L#M.33P(0>>Q!>?BR[I]N89=F2-Z.?B-W2KP,\]CW;3C' M3E?78 @"ZOW#H4*!^4S,:%W]=7FZ43V\J2ZC_=HQSTVU1Y_0;8C6?O(D*\>P MM23>Q6%[05*O7NMG2?!^]:1%86T%H\$GT#WF'*<_'!\='Y^0UPV4N%0UG'2W M]OE]DY;WB&?0#V7(&=3'E5^CHB$?<-MYC <]\([0&,\A;0C_HB,]2^A)]GV+ M?(:.(E&VSRYFWPOD+(K3/7?= ^["Y?=Y:\E8M!8B>O/%.F?^D>?G:]U:GSJ8 MKS*/LL]IME[SVGT*[6[UVIR>'?WRA9$J]YLC63IY#$,AON7?-PA!.!X-<$T, M:AP8+4.P])R]<\._S">)9<"LM!R'"DY=L%PQ.@FZZX3E(YVOSG&B87_( ']% MFY6#;%GAB6%'_I8QZIXEOQ1+6FC$LGPLV8[.6H[ID.5M>6_/$#O*$"XHO^G, M1,X@QE RC33)DF?B0![R=S@RI6)QLZ[>4:Z& M=^HUSX18D74-#B8 *SGU3HI_Y4 N1@C$%?ES"W8S*LC9L2H.X S.8YV17]3[ M'EBZRLGV-]A78.>@\XE"YI)>/G06S7!1"69;DM;0L6?47674I")TZS5W$H.V M=N'!-FX*H :^T2!>FB+\)VP XX7,+L";"'/"4WO+&.;.)_1>,Q$;!&O8"&01 M=*]O=9AC5,O#.I(_+HOAQ8F>-42DIQ18B;0@'+I(:PDRJ-20)MW\U2 M&&)#_)YHD)TH0'/TXH%HBUT7"-9+TC'8P_]A;*6U7JTX_-8;*C%0)-2'')DU20G>*%(Z\>%D M'KEWEUS+>,3.)\">MXR;G.*KV6*F&@Q](RB8P:?41X3; A./Q \G9P4(;)PF MQF!0-E JO'=QO7O#AOU"LZO7FD&VG@.KP>CR%0%O$+28$GW+D]KW*@Y22<'C M2[E8 U, 8V4AR,5CH8M@$!5P8O?J:YF^5QDB/),9F$*$ N:?MHPM]V[&NV56 MRQ#U&G/$>MB+E8.C)(J2.;+/E!XF$ 7(.C!;QHBHB*MP68S?N1@,* ?&@E*@ M;?S+8SF'\4'W+01.&H?L81G7?]EGC]/P.VISK2A/*#N) SC4<_DUWY MZ=2Z[66'1=9;80E*9,HLJ0Z+:D:@S8S MWD-X=W67_/:V>;.J(G-"#W(""-Q!,+<.*E"JR MC*?N990DTZ%*Q^+ZZ.9(' RE61XMG()BE"93\CNEW<&%G4[@MW8<'+% $@:LKDBF8L508NN'I)5B*C ] X3U*(\IF$CN M)^X&*6:J;-+7-('5Q<4%4VJH0\L@!=IB+:N8I"":D'H'P2$JP>@ 9G1= (N& M^$%B?:E3>WQ81 >YSXK6JY-BUNRDEP@\I)BJ!D(SE,>K>OHX24+L*YO<-YG\ M:?CG^ MUNZO21?:+LUV;_5^V:2BQS:IZ#HQ\/A@ B?#D;A4F+W <"M0*%QPY4B\08 @ M)>S/2(-7MSHDH6Y Z3(C&1#\W\::G0[BHLC40X8]8#:%UT,*1D2>Z4AF10J# M ]E0WKN-YZ'NY#(W2!_W6F379=%F@Z&,'J4XD]/8.CE=4!$>D":)Y1#L G\$ MI"=Z0VAPN'T#&27MMEM#N>@A9<.'\#Q,4+1F<(W*+,TUH@3D>V7S'B*,PC?( M!P"64$YQ4COH#!-KDDC%=AZ3!>O@EI RN 5&RISGT:4$9RI.F"R;_K]2VF!= M6G*]9N,$:^H"B(G"F"SZB^>HFM(,4$3X(YA&QF#6=$C9:FS9L668< #"%!/B MT'W CV0 J(]!E!M,0R-@E4U+*Q8&M&S0M%11** @G1'0E6#])B,OB6C E\#=-5J -*;/J#/"1+/,P( MV$CIHC(TL7YDL1HGF2:L;IE31-XF)M1X'E97+P)^T&G)A?=-[;\_HOLQB>X; M8!FN/_%<]!2(.4H*P.MXPJQT;VRA?_V>V '#X53J\^761QT$&S7 M;-R[U?[Y"R\W1D6P=@Z=])@#[J5LD8VV!ON(QZ]#*;-RT&1M/)EEWJEK4\'P M6(TY&$!UA,A[EWD:K,FGT\*F\4"?'N!DM1!<):_,K_@#K:9)/IZX#DJ4-'UL MP<>%N)$+5&\I)\T&#BJUT!JLP(\XT@^/.E7=MW)0GUC6)=@. MHRTV0<[353@J +,#;6,L5#P^+E41^(9=_1$80CR: \V0;S (\)4RJ+"2K+<1 MQ$J!!:T/*_CO.%G[:&''80"F,E6@B;$6YG0PFAH*!WO'W(W08[5 NHU+V)EA)ZBA05415C\3^-+R>KJ[F78CLFPX2') M*JY&*+W0545*-#QO$/E(ALJY5,K(X#!)WCMK'3.R5N)@I=$/]@_L>9)E:&WC MQ%#Q,JY"R=O5(X'S:_>\MZO:TF-;4HG<;>2K] !H=)3N-:EMXH2[T*2:IEXS M"9[L!M$-LQ0.9UORAET@&\12*5Y8M%BG[5)2/9[XDHI!PN$<6-W%^VB<%YT! M"NO$SX9\_?O&BY^.YY_NX_EW&\\_WC)9,?T?0J M@C)%NJT#<&%$"8S)G)+(5KWH0&!L32B*[M@BU075SI!*%4?J7,>4(5$&%MB)I/$:R(>%T,.5&U[) /*05&/.=:9DM'G*LK M@X VFV-I(YO5T113?0M,%$8+^W!#C'+T[E.D 4<<)[$$"QA(@$/LOAU;V[:A M[TZ9/B5E^BIE[D-X>5&=Z @85XS*7PSS%X9.L41U:991H&GEN;+NN\>-&W;' M4;W6YO#\A@?$/,FC4 1P%F&$::4[PHZ6IJ$,/N0Z7??@NGW(N5,L9NHUAQ+F MX%J<(X!WS__?1>+/CF_[S>JW7ZN--)53Z6G0[Q:V-^V7< MR6/GB8UX8?Y@;JIXM1+^0!_H O5N%1A76#Y4)1 3D(:* M4H3&F(*48MPQ)\@E[K5J#C%EXN06C^D*87LU9U '31X&D@(*-EHYQ'0<\W[! M=X0]-Z@L#59SX$'C5_7:9#'#71=(FR!%6W!.-Z30;53P MK>+KD- %Z==IDG94]C8MHI?@@,NS0M:8-Q!.,(.94KQG,9Q13@IE4Z>4UE4! MQU+"&,;PC(K^",>+17EF.B:H*_=F/V*OE7=US'4!*/"2#S$2BT;N,J[6A7N) M8+9$ET=E@6N?F&SQ)^8:O;!NDHD,O*?F5H(\1#FL/EK4',]&9?ZK,XCCX>#K MJNA&]=\KE[[":#07ZSBM7G.L=N18;>"%XO'F'CH"AACI0O-B:*''Z=*^<[-R MY+\_RE/KNJ XKRD-_HK7Q;? -OFAZ4V[('^T5>USDFPI1^[$**]H6X8O5 HL;W #KVG+"FR3B"@A,!#*]14WN0>4 M>K8EO/,]BN$M9+Q"3S^S-O)->;6E;R0O92'-,#N>\/D-J^-8]=W$DT(#P&F@.IQ<9NLM= MK\F\)>V*QCO6[&!:D\_&=Q\NM+T\-T;X@4TH+9S/!%>W_=5KWEB9>%LG.2WR M>>UP$SZ/&.VH>_;V79_=NZI3=:9SB)=.I+PUD5BJRL=(;/UE $6-YJ\ MJ5J9#7H;UIJ-%J[@T!24HA1OX+/.&5,ZJ^-LIIUQMI(QPX6VU014V&[9;#CBB4 MLK"5L'HY3/;)DR=K<[X]'R%Z-_?;?5>W^Q/:[F_XS+RQU6]7=S,?A&1.38KM M8ZH8%N1B%W*;)RE=PAYP)<@]_WP7#KO"F?IT-\:S2VO3:[UN7;9;V^)+W==" M^AKR^:GUDK5NG0^V8DC]N;OL2(4JKEKGJ]/]^L%Q43FR+'W*]MC>^;IC0'=I M@>[58QU49$H59B>G5^QI@\-S3:"YZ2[AW+(IW;/,%\B-L#*%*G]1 2[+)55%LLP O=H@W$-HJ< MEC$CNARQ($PNT)3NAP>/PC)Y9=M M.'--4>*2T0Z85>G"+[GA?0DB\A.$C$KD$WOH,#[ \23,K.2JU"HRBMT;KGOO M0MG#1I&8@SX-'1>)2=9'QUX\\AQ@WSH)R<-8%#>@:EA%LBAT,H%M0P@U="?& MRU JFS?D #ZNCI9S.WI^QDK_G.".7A#:T%Q?@OPG5*(NW#(6W6_!O[L%0ZM! M0/N]YJDW(J# AP]_S<.P\UD4Y!%/ MA[GB&\.'89C.AW5KJX>@.TNE[(M#D"6R?\9(!J,4>1VJ@&/826F*MT4P4!G[ M-\5]5.A(3(QVN&@N-N>=2CZ-)>[N2H7DYGA9()Y1IPK5TF%7.C5']@5;F!'C M%/.&'1K>M45CSL533>5O"!&("$KGS*_7BLKS M(Y Y6D:'RX-@1S\'(@@$F6DZP5,N2IJY"HN,5!S" M4%'2;=D^W,N9ORMGE$O)M0$[9+*EW-9DY/OQ+*U)(MVWG?&,5SMD?QW"V*YVR/XMGV';+S M9^]HV4L()Q.[7%;$/5<9Q_0::!EX@$XTE+Z)O6T3[4A;(1!+R6.28I'D5PI@ M.K=\-7U)->=*XOCE&E&- K\0U\5UM&G"6FH003]^U0PT&XQ_&O-M6J#QQRXO MW_JSO*+F? 23A8WWD;J.$+R$QY?.IV7-]7(V:"28YXE^@Y!O! !Z4H8G>%9& M):L1'5IV% 5BPAUNK* @"2J,W36FWN&(YM)VL>M^._[=[3@^%.T,O2KHXS2@ M!H+R-LHC_ZHRVJ:@DUDGE-L]T:+,X"WS?XU8@CWOH_.[&CUD&&:+1,MJ^)!P MF&M0D(A99+27152! 0^"B3"*<6&@4W5"+K\C+2[$>@\1(F@%'3%9O49^53;0 MEGST?JG5!KN.K,O1.SR6 M&Z/PL2VS*#>8J#;0A;0&^ MMV4/4,HHYQI#W$$U%K"ANX:8)7.G M[^E;C4FTRP?+I^AP&AG>_L-/T7:%/OC.#]1X4/.Q?:OBA:_B8/=RXKN 9A6PN9]W8SR[M#:OVWUT&C4[K>Z;/79N^T9] M=X?QSZX*$VJJE;(O-O^HN/-M0[%.ND:.E58=G/;B8#LU*[IPK7+"30.WQ^#O+LW[B''/K M6YL!4Y@BK"YP4=JXR+!#+E$C55G[-V('D;E MD* MS@2CJSB8J[%PC04(@M("JAUF2U-J-I6A<;$D6\H%J^&4-9%PF[AK&('? M(U2]P 0;E]? \54B93OUVD@&%!-27LX:7@J2)K$.N,#,5!O#D?[84\A"!.N$ M=N0$'S/)!LH=T9_L"Q1)KS-Q *;Q2*=3]N;9B3ID3R="$U"YSNA2^8(B&88X M=)P33#1,BCP^>PN\_=W"'%@KM/BB?CZDNJ3L#FV62*;4M;59%;UJ<0 M,E9L $+?)>E[<6!K6M=K-B_7E<]*7-7;$9@U;/<$D\2*++RIU+MXE2J#V#Q= MZ5*-;!#;KUL8HAL4-E89_KTMZ2M,NWK-1QT=WC?&_W08]^D^C'NW8=RG^S#N MG8C.>U6ER9/NG*9YE:3YM$S.=&!=ZRMTOD/4Z-"1CBH""U7R'6HSRPE&C\!D M=-'+E-QAN8M KKDK8,DJ(FBOC[!BYBS@GC8Q6V6HF%1 GTZ)63DY+/$%U2#3 MIR4*J?2?^:T504_JU2M-E<<9NTY7^J$:!G.%7D;C&J\0:#.Z;8OP!,\31J5G M,R4C86L,8N4'KLE8K]F[!_"-QDH6-5\1[/!2G-E=(L9PGJ8H$LCK9Q5K'@=7 MJ+33H=-4W28!%2,BQRD?<%2&ER\P5PN\ZWA>O=X;B:6RI)8@!^ $13BOXC!+ M$CWBAA3'P%LE[$-N?=/E!K&X9EDDLU[CYS#DC6M.U>YC;2%6^?2^'<+W1SZ= MD7QZI>@.12]_?&*_<7O4YHFQ2]VF.RRED4M*B#!PCML\B8*+4&N,(][A84(. M]K*@"P'!"Y3$/K*]XPSWE!BN"3(T)*B.O3]VLUO/RF^);Z#]/4U"OIH4BPM1 MB [-:"I\@SQ6K0-495 ^LDI\%&;6E-?&5^/6+#\=F:Y;9]"D+AI6P=FN'<"> ME7>5E7^V+C_14S8XW+1H\BZJ!9XT]3$\&W)3?"D*1AC6?/G$6QRGM+ZA%*ON M3&=1LK#X;+SU=^(7PH+]$VD&E-N(M(L=+T'S$8J$&J:MM9CXZ77DB$,4".H< M%J_DA7(+8O<,OZL,_PO+[@+^^5R\M)=4,%)IV6_E%;@OJJ[5[.\1[H-BCYE_!8R]XIVN$;#E M9%&21T5)OXY_S;2]@ 59TM;^F.GQ>/%P*(/WKMR'?U5 O>;P)LS]:RYDW[/@ M3K%@&[CO;7O0:?7[XNVK5J_5O:H"(DE9E50*IF1$CG*7HE53@60TM7*0JRFT M'SHEP5UP3@!'#A[*80*RS@K<>\=/I8O;=VDON[P_>PXJ'N^-GO$'Y,7U_-]_ MOH,UGO('SB=<>L?_;'MW.,^#2X^LBRY.<^>?#QY_]IQ^21)?MKMXHUM[\(Y) M:W?I.F/ M@ISF^KS]XI%YQ,2^E1\D'.K-R.@PU!_.'[5?[/GIFY%%D6!+R;;1QIS" MI)3LLF>5;T360&?1UO+*1:N[GC4L:N%;7^/TC1$T/S\77<+BF6?B6IIL#Z.Y M"QC-SW\51K.EH):[MT8?O>Q>OL/-^>C5X/7UB_\'4$L#!!0 ( /"&9E>> M$VR"-S/>[8'Q-Z2DL09AN.R>W;CPE?-),[B?_E5U<.6@+:05O; M^YAH"='92Z>[W6ZJFTTY[FU:W]W=3?>P34(UVNM-;)?1-#W]_?2D9K18FR:Y M[0EJ&VSPDL7M^^GP\>F@:<.U>*PIW@D[R:;'0,-3<_A"M'$NK1[&FHJ)3;=4 M4Q$VY9ZSF=&W?X6':C%XH3>MK8XX X7L^V'U9-A<3&X_;)H6+K6]IN.VJ8 Q M1$A;22V3S.0B0)(>,V* X#IUZSS^%LY.,JN'<,8&)TXI/FY0;\!QDXVP.^P3 M'L ;F6S8T&7-J6!S:7@:-O2]Y"VEG4'C)O4:LF'P( 85[KF.Q;R)K>636'/# M\6WA]B=C'#R,O>"Y8APTW(PU.JP7?PQ:-;@C7&YPT4\93ENVTS5@KU0O1DWX M2?#/@>#"8OF#M/H)3]M,4()0DNS!YX\?$T7'%LP6R7J_ _PVU-7'A& ]D59: MF,;WT@'8@W\ED^2(,\O<(S4F]LD9;;,]TC-[^Z12DK_<:)GBS57M0Z9T7"A< MP ]$CR233WT[F[U!8F_B1-Z$1#X#TN;AX*V7O+ZU>\- PH "^%MH,]N$?^+( MHKE]8_T8#@Y;+:KK^'%[E#H'3I1O] M)C .J@.X]1P8F9M:B[K,N\G<2%NH@'CRWG/@E!"7BP!6=@REJ< ;CMDGGNA; M[&.B"0*X1W2M(TB=MZ')&>N2JM.F]H:ZL0$(N+PI1=WDC^%[)OWLHL\Q%99!7W#29+54#+Z'AF=\&6(:2^IZHHO4H>.=-E)6DKDF#90.E M )[QO9@$)/)2! [2,4@O!SY1)A+YH5!,["D=(PL[!AO'7)AVF:=:H"G=\^0< M"1@0.?'MM:2=; BCGPS5(M7SS$3P6( I^)CP>+MC,:7^05=QX*H[S_'=L#=H M)L=X+Z"9<'.,YM TA4V9)'QP=W"?F_BDR9E+)/ILXJ13K'R),VGTY6%WZ8G] M!;UU@*>..8X%S/RN*%'!\D,20DC#9V.O@:!,>2E\,HI6#('P9L#&.&]]FRO& M@DJ-<;/-J.>[+!_HWAZT"8&%C^)=(+0I\)4B3^TB8()L].(^A@9CK!]0;AC& M<=[BNU()J'#X,,;00"LC M.JA,0FCW#M+P/OS$_PXZS[6Q^P2E+TDM?FOO$0,TA[G[I$W=6VXGA=/9(P!B M<*/A".&TY;U$_L#K4#O:7[))V]P"^_R;'F5;C_]D"L%$_K__UG/:_D$: 8(C MT\F_E)8GX#VX9[$F0-4F,2 Q1"(R*59]BR4OZ*WT":+S4I>;HH4(:A\2L0<- MQX4Q4N@<6M2X)YM @^=8W-PGP<,0-?5<3VT-6T3Y%&43CG?P_PAZZ1A^?Y^# M,Y..N9*+19;Y6="V(T>LD;\ZJ]3+I=656KU0+]<.THW%&\:0U%JY>%6MU"OE MVNI*X:Q$RM^+GPIGQV52/#\]K=1JE?.SA:0_$]#_K5#[5#D[KI^?;:RNE(HD MHVUM[BXDQ>]!<8_.JZ= CP2)WALN^W:UK%S:)I,EQ_!Q>821A!MCL/ >+L%_ M/CQ^*MJ7O)B[W0%X+UDF1?M(Y'>27T:710/>+T7L[=$&(@;FLEH^JZ^N5,L7 MY]7Z^Z_G4%JLKPH%V!@:"B9XECDOTK35SG3A-(EH,'_DN%QS@ MEWM&B]K@HA8,@8_UW>SFA;YCM$A@0GRR6USL/C>--.VMHV1H 1,,,HI(8Q,RB%"/>!UF8 38)!S&3W@$)A>P->[Z8C)CLAH* MVK 8]&99<-^0B7@M(:\[U#3#ZV?3'PEJ#6)5AF-9M.,!0N%O*J)[(-SG=_#( M7,$-:H7\ DZ'\>$#88Z$T$*N-R9'R9Y%4C;SX0\X1Z-&I1PS*A7;<%R8&&7R MO"9@BBFJI''1,:?8F#+]_'#9ONX=/C[/QD2F/LSK8TI#L([K/*).Q>>^)^"6 MR)^Q1VK2IU@B88Z/Y[-'Z_4':T2M)F&],%*X$Y/"(VXQ&$#P:R:+7/U3SMVY MV-:RY7\TJPV[P3R>GMS4MG/Z4H#>I #%S5B=]BI!&M:0YN)7TL2:%\?L[H>U M?6'^(W&:TFDBG]62VNY.=BO[5.&"_[FO/8$]O=AA0;R4-3EE1).GO__CN.1< MM&!Y]=EWN6=R%4IPFC%?1S)V,7@4FV(59<@"]Y;:_*>\&75A_ZDA_.O6[_WI M0-%IM[F'5;*+*L(XJ2N"E/E="NQ;'LVU2K7V/)-=;G;2;FV19,TV6>%_PXX3;3)WNU.=&MV#_ZQU<7 MV__(JYW082*?T;*K*U5F=AW')+66@_6T%]2][]+^%!=W8RS*?O@;NC)3O'5G MJUW]>GS?*\R8K$PB7_.Y8"2G:>\NGOG;:'/ J"+\>N[6G:X]>71*_G7O9\FH MY;;H+(9GV%TB'XC;Z@K>?+*4[4RB0JX$SMT+UWGDMC$EKE4HW5_<92_,*S/S MNG&MR4@E\D48;0!F\VE!K3%B=R<1>^$ !M8U[TP/X1WQW.']I?:Y?OK/T@23 M>DSD=S>UW-9[U*BU@!\R'7GAPJCR#K5(N<<,7_!'1LZ;,(\S;WUQN?#.YNI0 M =%$%5Q&IZN<>7B[5>A><5YD+U2Y:!_@*.>VM/4I2C9>-G44X'GB&-2Z:#GV M+\.M)X7SN^H5/7DXV7TAKJ/])/([V4Q2SV5R[](N('7#E.I__[V3T;?WP4P( M9K$.[# ZL^2N&*+&?-NW M!+69XWM6GWBP!/2:??EF\(+3 !IH$*64#R*9:1_@N*LKU.Z'#YN.!;WCB^B@ M<(P+>63M@.<]QG [1_Z8V@&1C0].T@&N)-GK]$[XZ6/E5/;JWT MY-S__-YJ-U]YO70?&"@-!CKM'NBV.F[UFZ&D/%NBK*RI"R%QFQ@1G ML'%23FQ!P!"$98YB?G^$57\Q&#B9N$7;]K+YX?5GL4:^CJ<0!B6M35*TJ.>] M?DW_W_&=7F&0])T_,T@N-0>K_UJ_W7 LLC:2'U\.U*\(V_PSVH3;0 ?*Q*C1 M(BST)V#* #,%=X;SRCSO;_CC'G28>P^FX+Z>:4C;--ECKG[]=GA?W"[K.ZT7 MYMY'^TGDT4T.2T=KPC'N-[!XCWREEL_(?[24IDW?J/(6?.2WM+R<5NT96$)E M R>+QF?OX?:HJ-'JX>T+12/622*/)]\N!_XO!_M"=0W79],W]V]?7I]FOIS? MM@KW_ZA $2WW>&WB)#P28/<]DSY,K3-"9A=IAPMJD5/JWC,QOXO(O[AX^#-$ M_YG\?,4V,>X WD"C3PRL%(F-T^;RV]9,CW,M!U*WNC(B=J.V M.!>KHPY?.Y8O%=4[DTUR9_O3[;6UU=YZ?+%)GAK?_ 4R3PYM+B7U;=G6)E;K M3;.66!VJ;"^)FUX^5OG7 L/*+&8(,*RV(\-[OL=D*Z @J"_$#V=P&?)3!X*C M5,J^K+Y4FBZ'OE%=;" 'KGLD7OP(MAK:AN8IJ>&_,0$HHJ?+3&I:WJJLM"< M%ES,KM%!<#%JAU-D(-*+.[[S8VM?_W3D&1]8'8N23#RR>K.S/+!Z[L4M0"(N M'\CZ?>CKP<!_CD?:14/VX M^ \C6Q/B57%N((OP#7."'DSF6SB2X:(J7%"%9^Z/LXO*/.UAC(!&Z%F@=N+$7@E:D^AU$?/5)Y@QP.O@9(*K:1(FNX6L5M MFQEM/PC!R"M]?YW($9+Q2VEJO(A $1K*4PS"0,H&,#K1 \Q5,A7;!UT1CJ5M M)L91?=O#,"9<&(XM9QF<(#OR6VFN6NNS6%]G<&/0#;+B((U%=75&'>+L2T(YJ M[V$L D/-#(/+;?!PX0H0QFVTAN5X1%V@PAS_,(L MQ#/*_%,D!H4(C^X.V?;>-.Q]VI4Z"J^4:&J; M&"=S?64CE(:T:1^4!A57ZD-<#E$]NBT'%!L$'7[O4%<,5$;*/N!^"P(:& '< MQ1N"")54Z2!HNL%P&S*5B1A88(/22S.E;WT@)O=D^"Y4$EU+FH#7UV^%"Z61 M V"(+H(0H'M2AS9"^T.H90UTP! M42*HK,;J2DPK-^3QW3X:7.:VO9&$5!S)*+LE9Z,,S6CC#+68YRF\UOBZO$,- M@6\$XX)FT1NFI0(S'_0[B72TQAQ J8"O,H"V,[$I$!+P8X1>$)2V+[% 1LJ* M8APD&2V.;",/91&?104K8,4D^:' '%Q>?,YWJ, QX.4PND#)^RD-*-JSD MJ&^)R(D9(-J@\)CML'B;"WF"PI[4O";EEH]N@J-T3 JUR2RC? "<%79?B!4//.-V7.)Z9\'C#B!(#A@@7NE+$ M2V./.2OI:"(W9 V!!P-H4;2<38Z)IO51J^2X$@W\%:<,$ \AMXWB3 GW<:)2 M#!$*/\GDD+M=+N>HI-_!1R&. :WX*FV"Q+@@HJ'QPU0NMWTYHPVZA3E#C:(< M&C6,X)\+VI>^NC3D#-Q"0TAC2,,L&P#(:=+\[2N#_HB>.>B7\$5D)A^0BJ+F M&(PASA[*,#@.4EQD*M"<+B0;@:,<&GJ$S ?6.MHE]!&",/HD @.NHIW36XJO M 90![. <$@5:BG8H>!(9:GM=G += 1*3Q5'E%V$:;T:VK!PQ4QY&%JX*YWEY/&NZ!Z.&ETJ3=<,)N8&3*5];*X MTE_0RAYKJZ5@TW7:@[RY6APVFZC*TBY=4"V%#E-LMX[T:-DPQ@"3_\/ *P\^"H3G^+H,7%H0K<'7[4-SW/1A(26_ M8Q](V6#Q*+=AA2$+7'AU4/+",GSX*0-&X,6[+)S\L<2MQ1M@D3=3N@027NL: MW,"E@W#4]!8#HLZ?"H^$!TC8DMLQA)>RO4Q-34M-O5H6*I/2LF\J!U5T&8U\ M4P']HA(H/TP71X/JJ?/(V6WHT41O*"<([S6;R<,@F%)K,29(8>BW*\##DP7G M-I7U]_5UT:F6;=9"^T99Y; XPBOS3 2P,\'P9X M-X4;A-^0 1[XV.&>9_S2MLP<1-;"\VMZ%[D2_!4&?,U<7UV)#.K?)W)Y0O4L M;.-K'&LR\QA%('?1+]#-_O02+35CQ/_H624SYGAI&&:=YW-&9DGU9DJ?U6<" MY_'LA9D*""4M%[?BF:%5=![QPRN(B=QN M5D%WD!JR_JU$!27XT5JRQL!;,#'7C#NM@PJCBFUQFY'OA]438CJ&CQ+VGD_F M_/5.TU=ZJ26!Y^[04CR:>=3;4PZXL7TK3XQJ._)W1#<@^<= MQQ5!D:BLMS6QX VKCQJL1:TF:?359^ED=B)H(?<2^)B!D "I+UJ."_C/1QW; M.Q# 61*'^R7VL!;R$=U+E^34IL9YH'89%GVK:[]?K;. <+S],9%Y-D]GB>)A MY;Q>K10K]1\*M=D9AJ7@:&)P:&L_OD7.9IO#UR@H=V+./$+X@3+Z.A MKZ,9 Q&>]-]!NN&8?=3>=$NTK7QR*-] M/?E%.#E0\CWVN7=T=Z5]Z=X5+EM7Z[?'6957L'I^7 MV]V?U]63])U_*>YJ67Y:*IQN9[./Q7KY\KRFG]Y=]C]]^VH72AT_H[=RK5[I MM)]IG1Y7MZ^-3O70Y]7FW<7QH^NGC4_7K2TR,#(S,3 S M,2YX2TR,#(S,3 S,5]L86(N>&UL4$L! A0#% @ \(9F5Q;; M>J=6!P V5< !4 ( !BPX &)T8WDM,C R,S$P,S%?<')E M+GAM;%!+ 0(4 Q0 ( /"&9E?0[8N,]"X !=8 0 * " M 106 !E>#$P+3$N:'1M4$L! A0#% @ \(9F5PAPZ>(C(@ SO D M ( !,$4 &5X-"TQ+FAT;5!+ 0(4 Q0 ( /"&9E>>$